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 Trust and its antecedents have been demonstrated as a barrier to the successful 
adoption of numerous fields of technology, most notably e-commerce, and may be a key 
factor in the lack of adoption or adaptation in the field of telemedicine. In the medical 
arena, trust is often formed through the relationships cultivated over time via clinician 
and patient. Trust and interpersonal relationships may also play a significant role in the 
adoption of telemedicine. The idea of telemedicine has been explored for nearly 30 years 
in one form or another. Yet, despite grandiose promises of how it will someday 
significantly improve the healthcare system, the field continues to lag behind other areas 
of technology by 10 to 15 years.  
 
The reasons for the lack of adoption may be many given the barriers that have been 
observed by other researchers with regards to trust and trustworthiness. This study 
examined the role of trust from various aspects within telemedicine, with particular 
emphasis on the role that trust plays in the adoption and adaptation of a telemedicine 
system. Simulators examined the role of trust in the treatment and management of 
diabetes mellitus (common illness) in order to assess the impact and role of trust 
components. Surveys of the subjects were conducted to capture the trust dynamics, as 
well as the development of a framework for successful implementation of telemedicine 
using trust and trustworthiness as a foundation. 
 
Results indicated that certain attributes do influence the level of trust in the system. 
The framework developed demonstrated that medical content, disease state management, 
perceived patient outcomes, and design all had significant impact on trust of the system.
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Chapter 1 
Introduction 
Problem Statement and Goal 
     Significant strides in the fields of telecommunications, networking, computer 
processing, software engineering, and infrastructure have created numerous opportunities 
for the advancement of telemedicine. Telemedicine’s definition encompasses a broad 
utilization of advanced telecommunications, networking, dissemination of expertise, 
distribution of information, and the exchange of healthcare information or services 
through geographically disparate participants (Chau & Hu, 2004). Yet despite the 
technological advances that have been made, the blending of healthcare and technology 
through telemedicine has historically remained 10-15 years behind the times 
(Goldschmidt, 2005). For example, technological treatment advances in organ 
transplantation, hypercholesterolemia, hypertension, diabetes, cancer, biotechnology, and 
numerous other procedures have dramatically increased the quality of life (QOL) of 
millions of people, while the positive effects of telemedicine have reached only a 
relatively small portion of the medical community and general population to date.  
The slow adoption of telemedicine may have numerous causes; however, the 
availability of advanced technology is not among them. Although a multitude of attempts 
have been made to establish and expand the adoption of telemedicine, most have been 
met with limited success. A problem exists that there is significant divergence in the 
adoption and adaptation of technology within the healthcare and medical community. It is 
suspected that this divergence, which may be rooted in a lack of trust in the technology 
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being applied, may hinder the advancement and treatment of patients, thus increasing 
morbidity and mortality.  
The idea of trust has been examined in several capacities and applications. Fogg 
(2003) has demonstrated that credibility and trust are key persuasive aspects of 
technology. If a user does not find the information or technology credible, they lose trust 
in the technology and ultimately abandon the innovation. Trust, when examined in the 
role of the service industry, has been challenging to define or isolate (Chang, Hussain, & 
Dillon, 2005). Trust may be influenced by several factors such as direct experience and 
varies greatly between individuals (Falcone & Castelfranchi, 2004). Trust may also 
influence the adoption or adaptation of technology, particularly in settings such as 
healthcare or medicine (Geffen, 2002). 
Relevance and Significance 
 The author’s goal in conducting this research was to offer a better understanding of the 
environment of telemedicine, revealing the factors that drive the adoption and adaptation 
of technology in the field of healthcare and medicine. Research has demonstrated that 
trust can have a strong bearing on the outcome of user adoption (Gefen, 2002; Fogg, 
2003; Chang, Hussain, & Dillon, 2005; Slyke, Belanger, & Comunale, 2004; Van House, 
2002). Ultimately, the purpose of telemedicine is to offer a higher quality of life to the 
patient. To that end, telemedicine functions in numerous ways. In this study, the author 
has considered the interactions between Patient-to-Clinician, Clinician-to-Patient, and 
Clinician-to-Clinician. The aging population of today is being confronted with myriad of 
diseases and conditions that require the collaboration of numerous clinicians and 
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specialists. In order to accomplish the goal of improving the quality of life for patients 
through telemedicine, there must be a certain level of adoption from all participants.  
Barriers, Issues, Limitations, and Delimitations 
 Historically, telemedicine has not evolved as quickly as other forms of technology or 
even medical advances (Goldschmidt, 2005); there are certain barriers that delay the 
process. Perhaps the climate of healthcare and medicine has not afforded the 
opportunities for technology to survive or flourish. Yet, despite the lack of major 
advances in telemedicine, it does continue to move forward, albeit slowly (Goldschmidt). 
Programs funded and promoted by governments have offered the greatest financial 
foundation for telemedicine (Raghupathi & Tan, 2002). These programs have poured 
millions of dollars into the research and development of telemedicine projects.  
 However, despite the funding and promotion of telemedicine programs, there appear 
to be other, perhaps less recognized barriers to the adoption by healthcare professionals 
overall. Adoption and adaptation have taken place on a micro level but have not 
expanded into the macro arena (Goldschmidt, 2005). It is hypothesized by the researcher 
that trust may have a bearing on this lack of macro adoption; thus a focused approach 
may elucidate and enhance the key aspects impacting the adoption on a macro level. 
 In terms of persuasive computing, trust, and deception, researchers Bradner and Mark 
(2002) found that geographic distance might lead to a reduction in cooperation and 
persuasion when perceived distance is greater. Moreover, there may be an increased risk 
for deception and lack of success with an extensive perceived distance, ultimately 
creating another barrier to the successful adoption of telemedicine.  
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 Another realm that may present limitations is the barrier of bias, which can surface 
from numerous sources. One such source is the author and researcher of this work. The 
author acknowledges a certain degree of bias in terms of selection criteria for this 
research. Other methodologies or examinations may serve to validate the final analysis of 
the data. In part, the author has selected a variety of literature from a trust and persuasive 
technologies perspective, as well as telemedicine collections. Examination focused on 
various contexts of innovation in both fields.  
Certainly there are numerous other barriers to overcome in order to succeed in 
telemedicine. This research does not purport to hold the key to success with telemedicine 
by solely examining trust, but also by identifying the trust factors involved such as 
quality and type of medical data, formatting and presentation of the information, and 
interpersonal dynamics. In this way, the line of thinking and general knowledge in the 
area of telemedicine will be advanced. Through this advancement in knowledge, it is 
hoped that an improvement is realized in the quality of life for patients. Future research 
may thus validate the results of these current findings, as well as facilitate their 
application and generalization to other areas. 
Elements, Hypotheses, Theories, and Research Questions 
The rapid expansion and development of the Internet over the past decade has changed 
the face of business. Businesses have been forced to deal with issues related to trust in 
order to establish customer relations comparable to the face-to-face business model 
(Slyke, Belanger, & Comunale, 2004). Trust dynamics have been explored and described 
in numerous e-commerce, health portal, and other web endeavors in an attempt to 
determine the role of trust in the adoption of these services (Chang, Hussain, & Dillon, 
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2005; Falcone & Castelfranchi, 2004; Fogg, Marable, Soohoo, Standford, Danielson, & 
Tauber, 2003; Gefen, 2002; Luo & Najdawi, 2004; Sillence, Briggs, Fishwick, & Harris, 
2004; Slyke, Belanger, & Comunale). Trust has emerged as a key component in the 
adoption rates of these technologies; a higher level of trust generally translates into a 
greater likelihood of adoption (Bryant & Colledge, 2002; Eastin, 2006; Kehoe & Ponting, 
2003; Lee, 2005). However, this philosophy may not easily transfer into a telemedicine 
model. This may be due to the fact that the risks associated with the use of a telemedicine 
model are quite distinct from those associated with other online models such as e-
commerce or health portals. The risks associated with e-commerce and health portals are 
perhaps a loss of privacy or money, while those associated with telemedicine are 
translated into undesired outcomes should the telemedicine model fail. Risks are also 
distinct and pronounced on both ends of the telemedicine spectrum. Patients may risk 
privacy issues, misdiagnosis, inadequate treatment, or unrecognized adverse events 
associated with medication, treatment, or patient compliance issues; all of which may 
lead to negative health related outcomes resulting in increases in morbidity or mortality. 
Clinicians in turn may not only experience the failed outcomes of the patient, but also 
risk liability for improper care or treatment. Consultative clinicians risk increased liability 
and loss of credibility, thus reducing new patient referrals or consultative opportunities. 
These risks represent a unique profile for the telemedicine community and may require 
an equally unique framework for the successful design of a telemedicine system.  
Considering the dynamic and distinct risks that may be associated with telemedicine, 
the adage of “increased trust equates to increased adoption” may not follow the same 
dynamics that are recognized in other online environments (Slyke, Belanger, & 
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Comunale, 2004; Sillence, Briggs, Fishwick, & Harris, 2004; Luo & Najdawi, 2004; 
Gefen, 2002). These are the questions that have been addressed by this research. What 
are the trust dynamics that may impede or support telemedicine? Are they distinct from 
other online services? Does the fact that trust has been shown to have an impact in the 
adoption rates in an e-commerce (Gefen) environment translate equally into telemedicine, 
since telemedicine reflects very distinct risks that may not be present in e-commerce? 
The hypotheses of this research were that trust and its antecedents have a strong 
bearing on the adoption and adaptation of telemedicine. Does trust impact telemedicine 
as it does other areas such as e-commerce (Gefen, 2002), health information web sites 
(Sillence, Briggs, Fishwick, & Harris, 2004; Slyke, Belanger, & Comunale, 2004), and 
other tenets of human computer interaction (HCI)? If so, what type of framework in 
telemedicine would need to be followed to maximize trust? Could a user form a different 
interpretation of telemedicine if trust concerns were addressed and eliminated?  
 The primary endpoint of this study was to examine the impact of specific trust 
dynamics on the field of telemedicine. This was achieved by focusing upon the disease 
state of diabetes mellitus. Not because diabetes mellitus has some unique issues with 
regards to trust, but rather diabetes was selected by the researcher due to its emergence as 
a global healthcare pandemic (International Diabetes Federation, 2006). The secondary 
endpoint of this study was to examine the impact of trust and telemedicine on various 
aspects of healthcare; specifically, perceptions and expectations between patients, their 
doctors, and other clinicians. Are patients’ perceptions unique from those of their 
clinicians? Are clinicians’ expectations altered when communicating with patients versus 
other clinicians? In order to effectively answer these questions, the researcher evaluated 
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the role of various communication pathways, attempting to discover specific nuances that 
may exist between them that are related to trust. Ultimately, it was anticipated that these 
discoveries would elucidate the lack of diffusion within telemedicine (Goldschmidt, 
2005; Tanriverdi & Iacono, 1998; Paré & Trudel, 2007; Greenhalgh, Robert, Bate, 
Macfarlane, & Kyriakidou, 2005; Robinson, Savage, & Campbell, 2003).  
The hypotheses of this research were based on examining trust dynamics within the 
health care community by examining the role of a telemedicine application. This was 
based on the communication links between members of the medical community, the 
patient and the clinician.  
Hypothesis: There is a significant impact on the trustworthiness of disease state 
management of diabetes based on the content and technical design elements of a 
telemedicine system, as well as the interpersonal relationships between the subjects. This 
hypothesis can be broken down into six sub-hypotheses. 
H1: The perceived content of medical information (i.e. lab results, kidney function, 
wound care, etc.) presented to the patient from the clinician will have a significant impact 
on the trustworthiness of the telemedicine application. 
H2: The perceived content of the medical information (i.e., diet, exercise, daily 
glucose logs) presented to the clinician from the patient will have a significant impact on 
the trustworthiness of the telemedicine application. 
H3: The perceived content of the medical information (i.e., diagnosis, medical 
therapy, disease state management and treatment options) presented to the clinician from 
the clinician will have a significant impact on the trustworthiness of the telemedicine 
application.                                                                                                                                                     
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H4: The design elements (i.e., how the site is displayed or represented to the user) of 
the telemedicine system will have a significant impact on the perceived trustworthiness of 
the telemedicine application, measured across all stratified groups. 
H5: The measure of perceived relationship between patient and clinician (bi-
directional) will have a significant impact on the trustworthiness of the telemedicine 
application. 
H6: Perceived patient outcome (bi-directional for patient and clinician) will have a 
significant impact on the trustworthiness of the telemedicine application. 
In order to evaluate the hypotheses, the researcher utilized surveys designed to 
incorporate and capture subject feedback data in relation to trust and telemedicine. 
Survey responses were measured based on scaled data in a uniform fashion, such as 
highest to lowest, yes or no, and strongly agree, agree, neutral, disagree, or strongly 
disagree. This scale provided a foundation for the framework being developed.  
This research explored the role of trust from the perspectives of both the patient and 
the clinician. Since both parties are paramount to the success of telemedicine, it was 
important to examine the roles and distinctions from each perspective. The researcher 
then developed a best practices framework that describes the role of trust within a 
telemedicine application. 
Definition of Terms 
Evidence Based Medicine (EBM): The conscientious, explicit and judicious use of 
current best evidence in making decisions about the care of individual patients. The 
practice of EBM refers to the integration of individual clinical expertise with the best 
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available external clinical evidence from systematic research (Sackett, Rosenberg, Gray, 
Haynes, & Richardson, 1996). 
 
Fasting Glucose Levels: Test performed to measure the concentration of glucose during a 
period in which the patient has not eaten. (Stedman’s Medical Dictionary, 2000)  
 
Glucose: 1. Blood Sugar.  2. Monosaccharide sugar that has several forms; an important 
source of physiological energy. 3. In diabetes mellitus, it appears in the urine. (Stedman’s 
Medical Dictionary, 2000) 
 
HbA1C: 1. Hemoglobin A1C, glycosylated hemoglobin, glycated hemoglobin. 2. A 
member of fractionated hemoglobin A to which D-glucose and related monosaccharides 
are covalently linked. 3. Concentrations are increased in the erythrocytes of patients with 
diabetes, measurement of which can be used as a retrospective index of glucose control 
over time in diabetic patients, typically over a three month time frame. (Stedman’s 
Medical Dictionary, 2000) 
 
Health Economics Outcomes Research (HEOR):  1. A multidisciplinary approach to 
examine the economic benefits when applied to the outcomes of healthcare. 2. Improves 
the state of healthcare outcomes by examining the disease management process to expose 
areas where economic improvements can be made. 3. Economic improvements are 
sought for the benefit of the patient, provider, pharmaceutical and healthcare providers or 
payers.  (Epstein & Sherwood, 1996) 
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Medical Informatics: Sciences concerned with the gathering, manipulating, storing, 
retrieving, and classifying recorded information within the specific field of medicine. 
(Stedman’s Medical Dictionary, 2000) 
 
Morbidity: 1. Relative incidence of a particular disease. 2. The ratio of sick to well 
members/people in a community or population. 3. The frequency of the appearance of 
complications following a procedure or treatment. (Stedman’s Medical Dictionary, 2000) 
 
Mortality: 1. State of being mortal.  2. Measure of the rate of deaths due to a particular 
disease within a given population. 3. A fatal outcome. (Stedman’s Medical Dictionary, 
2000) 
 
Salubrious: 1. Healthy: promoting health; healthful; favorable to health of mind or body. 
2. A healthy climate. [N. salubrity: Quality of being salubrious and invigorating] 
(Stedman’s Medical Dictionary, 2000) 
Summary 
Although telemedicine has been touted as having numerous opportunities and 
advantages in the treatment of patients, there has been a fundamental lack of adoption 
and adaptation throughout the healthcare community. The slow diffusion is seen from all 
perspectives including patient, clinician, providers, payers, and institutions. This lack of 
adoption may be present due to a variety of explanations, one of which may be trust. 
Trust has been demonstrated as a barrier in numerous other technological arenas, thus 
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telemedicine may equally have an issue with trust. Therefore, this research examined the 
role of trust in telemedicine applications from the perspective of the Patient-to-Clinician. 
It was hypothesized that trust does play a role in the diffusion of telemedicine. 
Specifically, this research hypothesized that there was a significant impact on the 
trustworthiness of disease state management such as diabetes based on the content and 
technical design elements of a telemedicine system, as well as the interpersonal 
relationships between the subjects. 
The researcher chose to examine the role of trust and telemedicine within the context 
of diabetes management due to diabetes being a worldwide pandemic (International 
Diabetes Federation, 2006). The growth rate associated with diabetes and impaired 
glucose tolerance (IGT), a form of pre-diabetes, is expected to increase 44% by the year 
2025 (International Diabetes Federation). That translates into a projected increase from 
500 million to over 800 million people impacted by diabetes (International Diabetes 
Federation).  
Numerous co-morbidities also exist with diabetes and IGT, which include 
cardiovascular disease, renal disease, macular disease, circulatory disorders, obesity, and 
nerve damage (International Diabetes Federation, 2006). Diabetes and IGT also affect the 
mortality rate, often reducing the life span of those inflicted with the disease 
(International Diabetes Federation). Although there is no cure for diabetes, the disease 
can often be managed through education, diet, and exercise. When these modalities fail 
though, the healthcare community can often offer diabetes management support through 
medical intervention. However, a significant burden lies on the patient to follow the 
guidelines and instructions of their healthcare provider.  
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Diabetes not only impacts the quality of life for patients, but carries an enormous 
burden on the healthcare community, global resources, and society in general. It is a 
complex and systematic disease, which may potentially be combated through advances in 
telemedicine. In turn, the field of telemedicine may benefit by generalizing the 
knowledge of trust issues gained from the study of diabetic patients to that of other areas 
of focus such as cardiovascular disease, which is globally ranked number one in terms of 
mortality. 
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Chapter 2 
Review of the Literature 
Introduction 
 
 The purpose of this chapter is to provide a review of the relevant literature associated 
with trust and telemedicine as it applies to the disease state of diabetes. This will 
encompass the areas of trust, telemedicine, medical informatics, and diabetes 
management. Additionally, the roles of trust, telemedicine, and diabetes management will 
be studied together to form a foundation for the development of a trust based 
telemedicine system.  
Trust 
 
 Trust has always been a cornerstone of the doctor-patient relationship. Patients must 
perceive a certain level of trust in their healthcare providers in order to follow their 
guidance and improve the quality of their lives. Establishing trust takes time, attention, 
and effort in human relationships; barriers to trust impede relationship development. 
Obviously medicine requires a high degree of relationship and trust in order to be 
effective. Chang, Hussain, and Dillon (2005) describe the issue of trust to be “fuzzy,” as 
in a vague sort of way. Trust is fragile, dynamic, and complex; one cannot readily place a 
specific definition around it (Chang et al., 2005). Trust may have a different meaning, 
look, or feel depending on who is giving the definition (Chang, 2005). It may also be 
measured by credibility (Fogg, 2003). In other words, a higher degree of credibility 
earned translates into having a higher degree of trust.  
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 Fogg (2003) also focused a great deal of attention on persuasive technology. 
Persuasive technology is designed to change the behaviors or thought processes of its 
users (Fogg). Certainly healthcare professionals are constantly attempting to persuade 
their patients to live better lifestyles by losing weight, monitoring diet, exercising, and 
avoiding unhealthy habits. Telemedicine is simply an extension of that process, allowing 
healthcare professionals to utilize technology to assist in persuading patients.  
 Examples of persuasive computing fall into the realm of trust and credibility, which 
have been examined in terms of Web site usage (Fogg, Marable, Soohoo, Stanford, 
Danielson, & Tauber, 2003). Focusing attention on the details of Web site design was 
found to have a dramatic impact on the perceived credibility of the site. There could be 
significant repercussions if designers overlook key credibility concepts. These 
repercussions could eliminate any benefit or perceived benefit to the user. In terms of 
telemedicine, this could have a significant impact on the outcome of the patient’s medical 
treatment, which would be unacceptable in a telemedicine application. Telemedicine’s 
success may hinge on many of the factors that are attributed to credibility and users must 
feel that the site is meeting the highest of standards, just as would be expected in a direct 
and personal patient management scenario. Telemedicine must be able to extend the 
credibility and trust dynamics to a virtual environment and potentially pay greater 
attention to these details than those which other ventures may require. 
 Trust was also examined in the realm of e-commerce (Gefen, 2002), where online 
consumers were evaluated for trust and trustworthy dynamics. Gefen found that these 
dynamics may have multiple facets with numerous effects. Many of these may be linked 
to beliefs, education, cultural norms, or other influential aspects of human nature. E-
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commerce, although small in relation to all commerce, may have specific challenges that 
other forms of commerce may not face. Human relationships, particularly in medicine, 
have a unique educational and cultural aspect that must be acknowledged and understood 
in order to adequately address the trust dynamics involved. It may be more difficult to 
establish a firm relationship with a customer, which is essential for persuasion to take 
place (Bickmore & Picard, 2005). Without the aspects of trust and trustworthiness, the 
consumer may feel less inclined to follow through with a commerce decision. These 
dynamics proved vital to decisions based on low personal importance (Bickmore & 
Picard) such as buying a pair of shoes or perhaps hotel shopping for an upcoming trip. 
However, when it comes to matters of high personal importance such as those associated 
with medical decisions, trustworthiness and likeability may be overshadowed by factors 
such as relationships. Bickmore and Picard introduced the concept of relational agents 
that would attempt to influence or persuade users that are considering matters of high 
personal importance; certainly telemedicine could be utilized in this manner. 
 Persuasive computing has also become a topic of interest over the past few years. 
Saari, Ravaja, Laarni, Turpeinen, and Kallinen (2004) examined the psychological role of 
persuasive marketing techniques in e-commerce. These techniques involve personalizing 
the presentation and flow of information specifically to the user in order to maximize the 
persuasive impact. Areas of potential impact could involve user interface, visualization, 
layout, modalities, or data structure (Saari, Ravaja, Laarni, Turpeinen, & Kallinen).   
 Knowledge work also carries with it a strong reliance on trust and trust attributes (Van 
House, 2002). Medicine has a high degree of knowledge representation and 
communication that is built upon prior research. In particular, Evidence Based Medicine 
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(EBM) requires a great deal of knowledge management, representation, and processing. 
EBM is often cited in diseases such as diabetes due to the overwhelming amount of 
research conducted. This research allows clinicians to follow the best known outcomes 
based on the evidence collected in large scale trials. Moreover, any Clinician-to-Patient 
relationship is knowledge work in process. The educated clinician is transferring their 
knowledge to the patient in the form of examination, diagnosis, and treatment. Van 
House indicates that a strong relation in the form of trust is required to effectively 
transfer information from source to source. 
 Communication is a cornerstone of medical care (Alpay, Toussaint, & Zwetsloot-
Schonk, 2004). Patients must communicate effectively with only their clinicians in most 
cases, while clinicians must communicate not only with the patient but with other 
clinicians as well. Healthy and constructive communication may be a function of a long-
term Clinician-to-Patient relationship. Telemedicine must be able to facilitate healthy, 
constructive, open, and accessible communication in order to function as a replacement 
for direct Clinician-to-Patient care. In addition, the medical environment today requires a 
multidisciplinary approach; thus telemedicine must also facilitate clear and open 
communication between health care providers.   
 Trust has also been examined in the realm of health information in which trust 
building dynamics were measured against online health portals (Luo & Najdawi, 2004). 
In these cases, the information exchange is less controlled and may not relate to accurate 
or current standards of care or treatment recommendations. In terms of online health 
portals, the study found that the trust dynamics examined were well represented. It was 
noted that the site designers may have employed measures that simply enhanced the 
26 
 
 
  
trustworthiness of the site, regardless of its effectiveness. Certainly design and content 
play a significant role in the increased trust or mistrust of an online health site (Sillence, 
Briggs, Fishwick, & Harris, 2004). These visualization techniques, such as the design 
elements, have been shown to be a barrier to trust in e-commerce and other online 
portals. In many cases, initial trust and early adoption can be increased through the use of 
visualization techniques in the design and formatting, yet long term trust and mistrust are 
impacted by the validity of the health information. Considering that telemedicine goes 
well beyond the simplicity of a health portal site, which is simply a repository for 
information, the necessity to examine the deeper roles of trust dynamics in telemedicine 
is warranted.  
Telemedicine 
  
 Although telemedicine has been a focus of extensive research over the past 40 years, 
adoption of the field has been slow (Goldschmidt, 2005; Wilson, 2003). Many factors 
may play a role in the slow adoption of telemedicine; however, availability of technology 
is not one of them. Availability should be distinguished from accessibility in that the 
technology may be present in and available on the world market, yet it may not be 
accessible due to government restrictions, poverty, internal politics, or lack of 
infrastructure.  
Despite the slow adoption of technology by the masses, each new technological 
advance has been adapted in some form by the medical field (Moore, 1996; King & 
Gribbins, 2002; Pinelle & Gutwin, 2006; Yu & Comensoli, 2004). This fact demonstrates 
the high interest level of the medical community. While telemedicine has failed to keep 
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pace with the adoption rate of other industries (Goldschmidt, 2005), they have recognized 
benefits in productivity, efficiency, and speed related to adoption of other forms of new 
technology (Moore, 1996; King & Gribbins, 2002; Pinelle & Gutwin, 2006; Yu & 
Comensoli, 2004).  
 Yu and Comensoli (2004) and Moore (1996) both describe the scenario where the 
medical system itself is unique in the adoption of technology. The medical community 
readily adopts technology in the form of diagnostic instruments, such as EKG machines, 
radiological imaging, cardiac imaging, diabetic monitors, laboratory equipment, and 
devices such as pacemakers.  However, this interest in technological instrumentation does 
not seem to translate into other forms of technology, such as healthcare information 
systems (HIS), telemedicine, digital patient records, or other informatics approaches. This 
reluctance may be due to the hierarchy of the healthcare system (Pinelle & Gutwin, 
2006). Knowledge is at the core of the healthcare system; clinicians spend countless years 
in training and education in order to become competent clinicians. This knowledge-skill 
relationship is locked up in a tight structure where top level opinion leaders in any field 
of medicine carry with them the key to disseminating and controlling the information 
flow through research directions, treatment guidelines, protocols, professional 
associations, and fellowships. Control of that information may be a factor impeding the 
adoption of technology. This hierarchy may cause those empowered with high-level 
knowledge to be unwilling to relent to its ubiquitous availability (Moore, 1996; Yu & 
Comensoli, 2004). As medicine becomes more advanced, each specialty becomes more 
complex and more information intensive.  
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It would be impossible for any one person to become an absolute expert in every field 
of medicine; its specialties are overwhelmingly diverse and complex. Moreover, each 
specialty is wrought with a hierarchy of control permeating the entire profession, 
resulting in a top down approach to information dissemination (Moore, 1996; Yu & 
Comensoli, 2004; Pinelle & Gutwin, 2006). Those top tier clinicians determine what is 
appropriate and considered best practice within a given disease state and push that 
information down throughout the system. Although there is no mandate that a clinician 
follow the opinions of the hierarchy, they risk the potential loss of credibility and 
malpractice should an approach that deviates from the standard go awry. By following 
protocols of best practices, clinicians demonstrate that they are abiding by current 
standards of care in patient treatment, thus reducing their risk exposure.  Therefore, there 
may be pressure within the system to abide by the status quo, thus resulting in less desire 
to adopt technology (Moore; Yu & Comensoli). 
 Moore (1996) further discusses the cultural roles within the healthcare system. 
Medicine has a certain culture that influences the adoption and adaptation of innovation. 
Each healthcare facility may carry with it a unique culture that either strengthens or 
weakens the adoption of technology. Moore elucidates ways in which negative cultural 
impact can be overcome, such as demonstrating a specific and clear outline of the 
outcomes of technology adoption to those at the top of the cultural hierarchy. In this way, 
the process of dissemination would be from the top down, thereby respecting the cultural 
nuances present in the medical system. By respecting the cultural distinctions of the 
hierarchy, Moore postulates that individuals at the top may be able to see the benefits of 
the use of technology. Lastly, Moore indicates that by changing the fundamental 
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approach to training clinicians, the benefits of technology can be seen earlier and the 
adoption curve may shift. One such approach may be to shift the conversation from 
information technology being of benefit to the clinician, to being of benefit to the patient. 
By demonstrating a clear and distinct benefit to the patient, the clinician may find it hard 
to argue against technology adoption. Moore concludes by indicating that failure of 
clinical systems has not been a failure of technology, but rather the shortcomings of 
communication and implementation of clinical systems.  
 Telemedicine, which has been loosely defined as patient management through 
disparate locations, has also carried with it an issue of presence (Alem, Hansen, & Li, 
2006), whereas the user may be influenced by the degree of presence as viewed by the 
participants. This research focused on the issue of trust within the realm of telemedicine. 
Failure to maintain a high level of presence in a telemedicine application could prove to 
be a major shortcoming and a major cause for the rejection of the technology.  Alem et al. 
considered the value of presence in patient care as it relates to the clinician-specialist 
arena, which is commonplace in the medical arena. Clinicians often seek the advice of a 
specialist to either develop a treatment approach or to confirm that an approach is 
appropriate. Presence in this sense creates a stronger relationship between remote 
diagnosis and care than between other modalities such as telephone-based systems. 
Presence factors help to determine the success of the remote consultation. Alem et al. 
utilized questionnaires to capture the results of the participants.  
 One area that has seen success in the medical informatics field, of which telemedicine 
is a subgroup, is that of radiology. Radiology consults have grown into a worldwide 
outsourcing phenomenon (Tanriverdi & Iacono, 1998; Greenhalgh, Robert, Bate, 
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Macfarlane, & Kyriakidou, 2005). This success is due in large part to the fiscal benefits 
met by such a system. The costs associated with having a radiologist on call during the 
night are overly burdensome. Therefore, if a medical facility utilizes a radiologist 
consultation on a case from, for example Australia or India, it proves to be very cost 
effective. However, this may also lead to concerns of licensing, training, and expertise 
from all parties concerned. Radiology and imaging certainly carry with it a large degree 
of subjective interpretation. Would these interpretations remain consistent if outsourced 
to other parts of the world? 
Many of the barriers that have been experienced by the lack of adoption of 
telemedicine may be attributed to fiscal accountability. To whom should the cost of the 
telemedicine system be addressed?  Numerous problems of this sort exist between the 
current healthcare system and proposed technological advances (Tanriverdi & Iacono, 
1998; Paré & Trudel, 2007; Greenhalgh, Robert, Bate, Macfarlane, & Kyriakidou, 2005). 
Others include the way in which specialists are traditionally reimbursed for consultations. 
Many organizations require a personal visit between clinician and patient in order to seek 
reimbursement (Tanriverdi & Iacono). Systems must be created that will support the 
myriad of stakeholders involved. These may include, but are not limited to, clinicians, 
providers, institutions, patients, reimbursement organizations, and developers of the 
technology. This poses a significant challenge, as each stakeholder may seek payment for 
the technology by another. Incentives are required that support changes in the system to 
adopt the technology. These changes could be the result of either policy changes or 
discovery of marketplace opportunities that benefit the providers in some way, as in the 
example of the success in outsourcing radiological services. 
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According to Tanriverdi and Iacono (1998), and Robinson, Savage, and Campbell 
(2003), as well as Paré and Trudel (2007), there exist numerous knowledge barriers to the 
diffusion of telemedicine. These knowledge barriers can be addressed through 
appropriate education, training, and a successfully navigated learning process in order to 
diffuse the technology and reap the benefits (Tanriverdi & Iacono; Robinson, Savage, & 
Campbell; Paré & Trudel). Unless the learning barriers are addressed at an organizational 
and institutional level, diffusion may remain low. This translates into incorporating the 
process early in the training of clinicians and adapting them to the overall benefits of 
technology.  
In addition to knowledge barriers being addressed, Tanriverdi and Iacono (1998) as 
well as Paré and Trudel (2007) suggest that behavioral changes on the part of the 
clinicians are necessary. Impact on roles, status, patient care, and autonomy must be 
addressed prior to the successful implementation (Tanriverdi & Iacono; Paré & Trudel).  
Another barrier may be legal in nature; many states forbid the practice of medicine by 
any person who is not licensed to do so in that state (Tanriverdi & Iacono, 1998; 
Greenhalgh, Robert, Bate, Macfarlane, & Kyriakidou, 2005). How will this affect the 
practice of remote care? If the primary benefit of telemedicine is to provide care across 
disparate locations, will these laws prevent the full use of telemedicine? Officials must 
grapple with the challenges faced by such scenarios in order to foster the technology. 
Ironically, the most money spent on promoting the use of telemedicine thus far has been 
by the United States Government, which has spent billions of dollars through various 
departments such as the Department of Defense, Indian Health Services, Health and 
Human Services, and the Department of Veterans Affairs (Goldschmidt, 2005). Yet 
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despite the enormous investment by the government, little attention has been placed on 
the legal issues surrounding telemedicine.  
 Medical informatics systems contain numerous components such as decision support 
systems, diagnostic tools, and evidence based medicine in the form of literature, image, 
video, and other tools. In addition, various medical informatics systems utilize a 
simulator to determine the effectiveness of a system prior to implementation (Lowery, 
1998; Jin, Kagioglou, & Aouad, 2006).  This research utilized such a simulated 
environment. Medicine lends itself well to the use of simulations to help foster the 
understanding and acceptance from the medical community. While Lowery (1998) and 
Jin, Kagioglou, and Aouad (2006) point out multiple approaches to the simulated medical 
system, one of its primary aspects is to determine its capabilities in matching the 
appropriate decision support system to the problem. 
 Adoption of technology by the healthcare sector is a multifaceted issue. The myriad 
issues related to why clinicians are reluctant to adopt the technology must be considered, 
as well as issues surrounding the security, privacy, accessibility, and protection of 
personal healthcare information.  Moreover, the persons or agencies responsible for 
maintaining and regulating the information must be determined (Huston, 2001).    
Li, Wilson, Stapleton, and Cregan (2006) discuss the demands on telemedicine that are 
beyond technical or knowledge management challenges, and deeply rooted in the human-
computer interaction arena. While rich media plays a prominent role in being able to 
appropriately diagnose a disease or well-hidden malady in the radiological or 
dermatological arena, cultural aspects of the medical community must also be considered, 
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extending from socio-technical to hierarchical understanding (Li, Wilson, Stapleton, & 
Cregan).  
Designers must have a deep understanding of the demands of the healthcare arena, 
which are based on tradition and training. Participatory design may be a leading factor in 
the success of telemedicine. Li, Wilson, Stapleton, and Cregan (2006) found that working 
closely with the users in the development of an emergency care telemedicine system was 
a key component to the success of the system. By utilizing numerous human-computer 
interaction techniques, such as heuristic evaluation, user testing, cognitive walkthrough, 
and cognitive task analysis, the developers may be able to better understand the needs of 
the healthcare community.  
Watts and Monk (1997), Monrad (2003), and Latifi (2004) consider the use of 
synchronous communications in telemedicine, which can be of benefit to underserved 
patients. However, they point out that the use of synchronous technologies often conflicts 
with the resounding push towards asynchronous technology expansion, such as 
radiological telemedicine. Yet, ultimately they proposed that there are five task 
characteristics that define the collaborative effects of telemedicine success. The first 
characteristic involves the oral aspect of expert consultations within the field of medicine 
(Watts & Monk; Monrad; Latifi). This may create additional demands on the technology 
to ensure that adequate voice and sound can be utilized effectively. The second 
characteristic emphasizes the many experts involved in a consultation (Watts & Monk; 
Monrad; Latifi). For example, a medic may contact the local emergency department 
seeking advice on the state of a patient suffering chest pain. In turn, the emergency 
clinician may involve a cardiologist or other expert based on the patient’s symptoms. The 
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third characteristic addresses the communication between clinicians and providers (Watts 
& Monk; Monrad; Latifi). In this case, a clinician must be able to quickly assess the 
knowledge base of the provider with whom they are speaking. Perhaps this person is not 
trained in specific techniques or does not possess the knowledge required to comprehend 
certain aspects. According to Watts and Monk, this will require that high quality sound 
systems be utilized in order for nuances in communication to be interpreted. The fourth 
characteristic of telemedicine success refers to the quality and relevance of the media 
(such as pictures or videos). Lastly, the patient’s perspective must be accompanied by a 
high degree of confidence in order to fulfill the needs of the system (Watts & Monk; 
Monrad, Latifi). Failure to gain the confidence of the patient may undermine the 
intentions of the entire telemedicine system (Monrad; Latifi). 
Chau and Hu (2004) found that the implementation of technology is a critical factor in 
the success for health care organizations. They paid particular attention to collaboration 
between clinicians, specifically specialists’ consultations of secondary and tertiary 
providers in the management of patients. Ultimately, Chau and Hu discovered that certain 
specialists seemed to have a higher adoption rate than others; most notably the surgeons, 
who adopted the technology almost instantaneously. It was also noted that the clinicians 
who had a higher adoption rate tended to be more involved in the adaptation and adoption 
stages of the project (Chau & Hu). Chau and Hu further describe the processes necessary 
for telemedicine and technology to actually succeed, which involves properly addressing 
the challenges faced by the healthcare industry in terms of both technology and 
managerial issues. It is not a question of whether or not the technology will drive the 
changes, but rather how the technology can foster changes. Furthermore, the speed and 
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efficiency by which the healthcare community addresses the issues faced are also 
pertinent (Chau & Hu).  
Raghupathi and Tan (2002) consider the exponential growth of the implementation of 
information technology by the healthcare industry through the use of telemedicine, 
healthcare recordkeeping, hospital information systems, and the broader dissemination of 
health related information. However, significant challenges exist for those who attempt to 
implement health care related decisions within a technology based system (Raghupathi & 
Tan). Changes in the business model within the health care industry must shift from a 
revenue and cost containment perspective to that of patient outcomes. This model focuses 
attention on disease prevention and appropriate therapies to minimize the impact of the 
disease on the patient, and subsequently, on the health care system.  
Additionally, Raghupathi and Tan (2002) introduce a framework of systems 
integration that separates the system into an internal and external approach. Internal 
integration focuses upon the ability of an organization to integrate multiple systems 
within an organization. External integration focuses upon the ability of an organization to 
integrate with outside organizations and systems (Figure 1). The area where they merge 
reflects the domain of telemedicine. 
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According to Raghupathi and Tan (2002), the use of data warehouses within the 
medical community often allows for the analysis of disease state trends and issues. These 
issues may have been unnoticed or disjoined in prior research, as they may have been 
hidden in plain site. For example, prior to the examination of data from the Framingham 
Study (1948-Present; American Heart Association, 2007), little was known about the 
cause and effect of diabetes on the cardiovascular system. Today, however, diabetes is 
considered a central factor in the development of cardiovascular disease. Oftentimes, 
unless major clinical trials are developed with specific outcomes research tied to them, 
these questions are never even asked, let alone answered. The utilization of telemedicine, 
a subset of medical informatics, can help to correlate disease specific questions so that 
further research can help to elucidate what is truly happening. The ability of this analysis 
also lends itself to deeper analysis of epidemiological or Health, Economic, and 
Computerized 
Patient 
Records 
Document 
Management 
Data 
Warehouse 
Health 
Information  
Telematics 
Web-based 
Technology 
Network/ATM 
Internal Integration 
External Integration
Figure 1 An Integrative Strategic IT Framework (Raghupathi and Tan, 2002). 
Copyright 2002 by ACM. Used with permission. 
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Outcomes Research (HEOR). This results in better cost analysis and prevention, as well 
as in leading researchers on the correct path to a cure.  
One of the largest data warehouses ever created by any one agency was announced in 
1999 by the United States Department of Defense (DoD). Their plan included the 
development of a data warehouse in order to afford better care for enlisted members, 
retirees, and their families (Raghupathi & Tan, 2002). The DoD is currently attempting to 
convert from a cost containment model to a managed care model while utilizing the data 
warehouse to better serve its patients. The system, known as Computerized Executive 
Information System (CEIS), is expected to house information regarding nearly 8.5 
million patients (Raghupathi & Tan). The system has gone through numerous iterations 
and is currently at the heart of the Military Health System (MHS), containing features 
such as decision support and medical surveillance.  
Another issue raised by Raghupathi and Tan (2002) concerns the networking 
technology deployed in health care systems, such as asynchronous transfer mode, or 
ATM, which is quite agile in the transmission of multimedia content with little or no 
degradation. Telemedicine applications may require a high degree of media content in 
order for the clinician to fully elucidate the treatment and care of the patient. 
Technological resources that allow for a greater throughput and bandwidth may be 
required to accommodate the demands of high end image capture, transmission, and 
display devices.  
Medical informatics, telematics, and telemedicine all encompass a wide variety of 
information demands. For example, the technologies may deal with clinical, biomedical, 
biological, chemical, biochemical, statistical, or cognitive analysis of information 
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(Raghupathi & Tan, 2002). These demands place an enormous burden on the technology, 
as well as its producers and managers. Such burdens include the management of ethics, 
privacy, security, standardization, governmental regulation, healthcare reimbursement, 
storage, retrieval, and processing concerns. Additionally, these systems often employ 
complex and demanding algorithms such as neural networks, artificial intelligence, fuzzy 
logic, decision support systems, and clinical decision tools. These algorithms require 
expertise throughout their development, deployment, management, and utilization 
(Raghupathi & Tan). 
 The high level demands that are required to produce adequate results in the field of 
health informatics will require attention to numerous details and challenges. Many 
promises have been made regarding the potential benefit of technology in healthcare, yet 
its advances are often isolated and difficult to quantify. This may be a result of poor 
adoption or adaptation; however, many of these issues more likely evolve from a lack of 
standardization, cost overruns, poor strategic planning, and implementation challenges 
(Raghupathi & Tan, 2002). 
 
Diabetes 
 According to the American Diabetes Association (http://www.diabetes.org), diabetes 
is a disease in which the body is unable to produce or adequately utilize the hormone 
insulin. The body utilizes insulin to generate energy from foods such as sugar, starches, 
and other dietary sources, which are converted into an energy store known as glucose. 
Insulin acts as the key with which glucose may enter the cells and supply it with energy 
and nutrition. Without an adequate supply of properly functioning insulin, the glucose 
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levels increase in the bloodstream and are unable to nourish the cells, resulting in high 
blood glucose levels.  
The disease spectrum of diabetes includes a number of specific types such as Type 1, 
Type 2, Gestational, Impaired Glucose Tolerance (IGT), or pre-diabetes. The spectrum 
includes those persons who have not yet developed diabetes, but present with signs and 
symptoms that indicate predisposition to the disease. Numerous co-morbid conditions can 
lead a clinician to suspect that a patient is diabetic or pre-diabetic. These co-morbid 
conditions include but are not limited to: coronary artery disease, peripheral vascular 
disease, erectile dysfunction, retinopathy, neuropathy, and obesity.   
Type 1 diabetes refers to the body’s inability to produce insulin (National Diabetes 
Information Clearinghouse, 2007). Insulin facilitates the passage of glucose from the 
blood to the cell to be utilized as an energy source; the lack of insulin causes a rise in 
blood sugar glucose resulting in cellular damage. This condition was previously referred 
to as juvenile diabetes, or insulin dependent diabetes mellitus (IDDM), because it was 
historically diagnosed in children or young adults. The term Type 1 is now considered the 
official diagnosis, replacing juvenile and IDDM, where the body is no longer producing 
insulin, or is producing a very low volume. Patients who fall into this category require 
insulin injections in order to survive.  
Insulin is normally produced in the pancreas via beta cells. Oftentimes, persons who 
suffer from Type 1 diabetes may be able to produce low amounts of insulin, however, 
over time these beta cells within the pancreas eventually burn out, resulting in a loss of 
insulin production. There is no cure for Type 1 diabetes. Yet it is not uncommon for Type 
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1 diabetic patients anticipating a kidney transplant to occasionally receive a dual organ 
transplant of a kidney and pancreas, resulting in a newfound ability to produce insulin.  
Type 2 diabetes, sometimes referred to as non-insulin dependent diabetes mellitus 
(NIDDM), results when the pancreas produces insulin but the body’s response to the 
insulin is flawed in some way, which is known as insulin resistance. Insulin resistance 
refers to the inability of the body to respond correctly to the insulin released by the 
pancreas. 
Impaired glucose tolerance (IGT) is a condition common with pre-diabetes. In this 
case, the patient suffers from a rise in postprandial glucose levels, which occurs when 
glucose blood levels increase but are not sustainable to warrant a diagnosis of diabetes 
(International Diabetes Federation, 2006). However, eventually transition to Type 2 
diabetes occurs in up to 70% of persons suffering from IGT (International Diabetes 
Federation).  
Globally, diabetes mellitus is one of the most common non-communicable diseases, 
continuing its ever increasing pandemic (International Diabetes Federation, 2006). It is 
estimated that by the year 2025, when the world population reaches nearly 8 billion 
people, 6.3% will suffer from diabetes and nearly 9% will suffer from IGT (International 
Diabetes Federation). This represents nearly 800 million people worldwide suffering 
from complications of diabetes or IGT. Currently, diabetes ranks as the fourth or fifth 
leading cause of mortality in developed countries, while developing countries are also 
experiencing rapid increases in the diabetic population (International Diabetes 
Federation).    
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Health costs associated with diabetes are staggering on a global scale. Developed 
nations have some of the highest levels of diabetes and therefore cannot simply pass the 
burden off as an economic, social class, or third world issue. Diabetes is a global 
pandemic and management of this disease is critical for the public health system 
worldwide (International Diabetes Federation, 2006).   
 This research was focused on the area of diabetes, which follows specific medical 
intervention guidelines and protocols in order to avoid complications that may be renal, 
retinal, cardiovascular, or podiatric in nature. Tests that measure blood glucose levels, 
HbA1C, and other metabolic systems can help determine the probability of experiencing 
certain complications. Research such as the Framingham Heart Study (1948-Present; 
American Heart Association, 2007) has demonstrated the risks associated with diabetes. 
This study, which has been tracking patients and their descendents for nearly 60 years, 
specifically helps to calculate the risk of having an ischemic event such as a heart attack 
or stroke over a projected five-year time period. Calculations result in a probability score 
reflective of the overall risk level. Similarly, probability statistics associated with the risk 
factors of diabetes were used in this study, and the simulators utilized included a 
prediction of patient’s risk of diabetic complications. Since the medical literature 
provides a rather strong approach to probability indicators, a decision support system 
utilizing Markov Chains Monte Carlo were employed in the simulators. 
Trust, Telemedicine, and Diabetes 
 Although a number of researchers have explored the issues of trust (Fogg, 2003; Fogg, 
Marable, Soohoo, Standford, Danielson, & Tauber, 2003; Falcone & Castelfranchi, 2004; 
Chang, Hussain, & Dillon, 2005; Slyke, Belanger, & Comunale, 2004), telemedicine 
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(Wilson, 2003; Watts & Monk, 1997; Raghupathi & Tan, 2002; Li, Wilson, Stapleton, & 
Cregan, 2006; Huston, 2001; Chua & Hu, 2004; Alem, Hansen, & Li, 2006), and diabetes 
(American Heart Association, 2007; International Diabetes Federation, 2006; Kahn & 
Weir, 2004; Khaw & Wareham, 2006; National Diabetes Information Clearinghouse, 
2007) on an individual scale as noted above, there are limited instances in which the three 
have been studied in any combination (VanHouse, 2002; Tanriverdi & Iacono, 1998; Paré 
& Trudel, 2007; Sillence, Briggs, Fishwick, & Harris, 2004; Moore, 1996; Luo & 
Najdawi, 2004; Goldschmidt, 2005).  Furthermore, there are no known studies in which 
all three aspects have been combined.  
Contributions of this Research  
This research was designed to extend beyond what has already been examined in 
relation to trust and telemedicine. Although trust has been examined in a number of roles, 
in particular e-commerce, there has not been a study examining the specific role of trust 
in a telemedicine application. Other research conducted on trust (Fogg, 2003; Falcone & 
Castelfranchi, 2004; Gefen, 2002; Luo & Najdawi, 2004) has indicated that the trust itself 
can impede the adoption of the technology. E-commerce, for example, has benefited 
greatly from the advances in trust research (Gefen, 2003). Although it is reasonable to 
assume that less trust in telemedicine would translate into less adoption, is there 
something unique or different about telemedicine that would require a unique 
framework? These nuances are where this research was focused, attempting to elucidate 
the factors that may or may not make telemedicine distinct from other forms of 
technology. This study attempted to contribute to the field in several ways. First, the 
research adds to the growing abundance of literature in the field of medical informatics 
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and trust, allowing researchers and developers to create a better understanding of the key 
aspects of diffusion associated with telemedicine. This research focused on patient care 
and management in a virtual environment and considers trust dynamics that may play a 
key role. Secondly, this research contributes to organizations that are in the process of 
developing and implementing telemedicine applications, allowing them to better 
understand and improve upon dynamics that foster trust in the virtual environment. 
Summary  
The literature provides numerous analyses on the issues facing the areas of trust 
(Fogg, 2003; Fogg, Marable, Soohoo, Standford, Danielson, & Tauber, 2003; Falcone & 
Castelfranchi, 2004; Chang, Hussain, & Dillon, 2005; Slyke, Belanger, & Comunale, 
2004), diabetes (American Heart Association, 2007; International Diabetes Federation, 
2006; Kahn & Weir, 2004; Khaw & Wareham, 2006; National Diabetes Information 
Clearinghouse, 2007), telemedicine (Wilson, 2003; Watts & Monk, 1997; Raghupathi & 
Tan, 2002; Li, Wilson, Stapleton, & Cregan, 2006; Huston, 2001; Chua & Hu, 2004; 
Alem, Hansen, & Li, 2006), medical informatics (VanHouse, 2002; Tanriverdi & Iacono, 
1998; Sillence, Briggs, Fishwick, & Harris, 2004; Moore, 1996; Luo & Najdawi, 2004; 
Goldschmidt, 2005), and related topics. However, there existed a gap in the information 
tying them all together. Considering the poor adoption rates of telemedicine, the need for 
broader healthcare initiatives to support those in disparate locales, the rapid increase in 
the prevalence of diabetes, and the vast amount of evidence that correlates the adoption to 
trust in other fields, the need for closer examination of trust in telemedicine was 
warranted. What aspects of the lack of adoption of telemedicine are directly attributable 
to trust? Is there a framework that would improve upon the success of telemedicine? The 
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literature provides rich sources of trust research in areas such as e-commerce, health care 
portals, or other online services, but there is limited data on the issue of trust in terms of a 
specific disease management, such as diabetes, through telemedicine. 
Diabetes has quickly become a global epidemic and is projected to increase 
dramatically in the foreseeable future. It is a slowly progressing disease that often 
translates into increased morbidity and mortality for those who suffer from the disease. 
Many of the ramifications associated with diabetes can be reduced by consistent and 
proper management of the patient’s disease through diet, exercise, medications, and close 
monitoring of disease parameters. Diabetes management blends well with a telemedicine 
system. Often management of the disease comes from acute observations of glucose 
levels, diet, patient education, and constant reinforcement, which are all areas where 
telemedicine could offer a potential benefit.
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Chapter 3 
Methodology 
 
 As the population continues to age, advances in medicine have extended the life span 
of people throughout many parts of the world. Along with the increase in life expectancy 
comes an increase in co-morbidity of disease states within a single person. Oftentimes, 
multiple clinicians will be treating the same patient, increasing the likelihood that issues 
with communication between treating clinicians may arise. Telemedicine could provide 
an opportunity to increase the affordance of communication and ultimately quality of life. 
This study approached the issue of trust by examining trust dynamics from three 
perspectives: Patient-to-Clinician, Clinician-to-Patient, and Clinician-to-Clinician. 
Examining the trust dynamics from multiple perspectives allowed for a framework to be 
developed that incorporates these dynamics into the design of telemedicine applications. 
Thus, improved trust dynamics could potentially increase the credibility of telemedicine 
applications from the perspectives of the users. 
 It is important to recognize that this research was not focused simply upon online 
health portals. Indeed, numerous studies have been conducted assessing the value, 
trustworthiness, credibility, and impact of online health sites such as those from Gefen 
(2002), Luo and Najdawi (2004), and Sillence, Briggs, Fishwick, and Harris (2004). This 
research extends beyond online health sites, aspiring to a more robust approach to patient 
care in which the clinicians and patient can interact, communicate, diagnose, treat, and 
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manage conditions through the use of technology. In order for such an experience to take 
place, there must be a certain degree of diffusion of the technology to create such a 
virtual environment. 
By building a framework based on prior research with regard to trust, it will be 
possible to extend the reach of these frameworks to a more generalized form. A single 
web site was designed to encompass three aspects of users: Patient-to-Clinician feedback, 
Clinician-to-Patient feedback, Clinician-to-Clinician feedback. Measuring each of these 
areas against the hypotheses has allowed for increased understanding of the impact of 
trust on telemedicine ventures. 
At this point, it is helpful to revisit the hypotheses of this research, which were based 
on examining trust dynamics within the health care community with a focus on the role 
of a telemedicine application.  It was hypothesized that there is a significant impact on 
the trustworthiness of disease state management of diabetes based on the content and 
technical design elements of a telemedicine system, as well as the interpersonal 
relationships between the subjects. This impact was measured through the use of a 
detailed survey questionnaire, which was designed to draw distinctions between specific 
and detailed nuances of trust factors that influence the adoption and adaptation of 
telemedicine. This hypothesis is broken down into the following six sub-hypotheses. 
H1: The perceived content of medical information (i.e., lab results, kidney function, 
wound care, etc.) presented to the patient from the clinician will have a significant impact 
on the trustworthiness of the telemedicine application 
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H2: The perceived content of the medical information (i.e., diet, exercise, daily 
glucose logs) presented to the clinician from the patient will have a significant impact on 
the trustworthiness of the telemedicine application. 
H3: The perceived content of the medical information (i.e., diagnosis, medical 
therapy, disease state management and treatment options) presented to the clinician from 
the clinician will have a significant impact on the trustworthiness of the telemedicine 
application. 
H4: The design elements (i.e., how the site is displayed or represented to the user) of 
the telemedicine system will have a significant impact on the perceived trustworthiness of 
the telemedicine application, measured across all stratified groups. 
H5: The measure of perceived relationship between patient and clinician (bi-
directional) will have a significant impact on the trustworthiness of the telemedicine 
application. 
H6: Perceived patient outcome (bi-directional for patient and clinician) will have a 
significant impact on the trustworthiness of the telemedicine application. 
The research explored the role of trust from the perspectives of both a patient and a 
clinician. Since both parties are critical to the success of telemedicine, it is important to 
examine the roles and distinctions from each perspective. Using information gained from 
this examination, the researcher then developed a best practices framework which 
describes the role of trust within a telemedicine application. 
 In developing the web site-based simulation for this dissertation, the researcher 
utilized a Markov Chains Monte Carlo process as a simulated decision support system. 
This approach has been used extensively in the medical simulation environment 
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(Shortliffe & Cimino, 2006; Tan, 2002). It is a stochastic process utilizing the Markov 
Chains property, which, under probability theory, considers the sequence of random 
variables designed to determine the probability of future events based on the current 
states. This research will focus on three states of a patient: salubrity, morbidity, and 
mortality. Each of these states will be based on probability statistics of the patient’s 
current state. For example, if a patient has HbA1C test results greater than 7, the 
likelihood that the patient will experience co-morbidity of their diabetes increases. 
Research has indicated that HbA1C is a strong marker for future events (Khaw & 
Wareham, 2006). This can be translated, along with other factors, into Markov Chains in 
order to predict future outcomes based on a current state (Shortliffe & Cimino). 
 The purpose of the simulators was to allow the subject to experience an environment 
which incorporates the various aspects of trust that may be important for telemedicine 
adoption. By utilizing a simulator, the researcher was able to gain insight into the aspects 
of trust that are key environmental factors for the framework. The simulators offered an 
environment that is free from the difficulty of running a real world test, yet approximates 
the conditions and the environmental variables that may play a significant role and 
answer the primary questions posed by this research. Once the subject had experienced 
the simulated environment, a comprehensive survey was used to determine how the user 
experienced trust. The user compared a baseline of all of the trust dynamics to a subset of 
the trust dynamics. This allowed the researcher to isolate specific factors that play a more 
significant role in the trust equation. From this, the researcher was able to develop a 
hierarchy of trust dynamics which were utilized to build the framework. 
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 In order to effectively test the hypotheses associated with this research, an evaluation 
of the current “best practices” associated with telemedicine was essential. These “best 
practices” were incorporated into simulators that examined the various aspects of trust 
and trustworthiness as it relates to telemedicine (Loane & Wootton, 2002; Stanberry, 
2006; Yellowlees, 2005; Chang, Hussain, & Dillon, 2005; Falcone & Castelfranchi, 
2004). As the methodology was developed and the trust parameters were established, two 
trust experts were used to help validate the model. Within the context of this research, 
trust experts were defined as individuals who have conducted research or work in the 
field of human relationships and trust, interpersonal trust, or trust and credibility work in 
other areas. Trust experts utilized had a background in psychology, psychiatry, human-
computer interaction, or diffusion of innovation research. Trust experts were surveyed to 
establish the trust baseline and assign weights to each trust dynamic that were 
incorporated into the simulators. 
 The researcher examined diabetes as the specific disease state within the telemedicine 
application. Diabetes was selected due to the prevalence of the disease worldwide. In 
developed countries, diabetes ranks as one of the top five causes of mortality 
(International Diabetes Federation, 2006). It is linked to numerous other diseases such as 
hypertension, coronary artery disease, ischemic events, stroke, diabetic neuropathy, 
vision loss, amputation, renal disease, and organ transplantation (Kahn & Weir, 1994). 
Diabetes poses an enormous burden on the resources of the global healthcare institution, 
both from an economic and human resources perspective. It can also be a slowly 
progressive disease (International Diabetes Federation, 2006); sometimes taking years to 
fully realize its devastating impact. Appropriate management of diabetes is imperative to 
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ensure quality of life and avoid premature morbidity and mortality. This is achieved 
through diet, exercise, regular blood glucose monitoring, and consultations with 
clinicians. As diabetes requires in-depth, consistent, and long term disease management 
its treatment creates a unique opportunity for telemedicine. An effective telemedicine 
application could facilitate the management of diabetes and dramatically improve the 
quality of life for millions of people.   
 The following outlines the specific steps that were required in designing the 
quantitative portion of the telemedicine framework. These steps include: 
1. Simulated Interactions: 
a. Patient-to-Clinician (Simulator 1) 
b. Clinician-to-Patient (Simulator 2) 
c. Clinician-to-Clinician (Simulator 3) 
2. Experts and Evaluators Utilized: 
a. Group 1:  Two trust experts validated the trust dynamics chosen 
b. Group 2:  Two medical experts validated telemedicine simulators 
c. Group 3: One patient and two clinicians pilot tested the simulators for 
programming errors. 
3. Research Phases: 
a. An exhaustive literature review was conducted, focusing on the human 
computer interaction (HCI) area of trust dynamics. From this focus, the 
researcher generated a manageable list of 10-15 trust dynamics specific to 
telemedicine. Two trust experts were used to validate the trust dynamics 
selected. 
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b. IRB approval was acquired as required for the study.  
c. A survey was developed to confirm trust dynamics (Appendix B). 
d. Trust experts were surveyed (Appendix E) to validate the key trust 
dynamics, 
i. Survey was used to rank the trust dynamics  
ii. Validated rankings were used as the basis for trust dynamics 
simulators 100%, 75%, 50%, and 25%. The simulator with 100% 
of the trust dynamics was considered baseline, while the 
percentages of 75, 50, and 25 represent the subset of data that was 
compared to baseline. This allowed the researcher to isolate 
specific nuances of trust dynamics that may play a more important 
role in the framework.   
e. Existing telemedicine models were surveyed by attending the American 
Telemedicine Association (ATA) and the American Medical Informatics 
Association (AMIA) conventions. By examining existing systems and 
validated approaches, the researcher established best practices standards 
that can be used to develop the simulations. 
f. A framework was developed utilizing the best practices standard from step 
3e.  
g. The controlled study was enacted using all simulators and questionnaires 
through the uniform resource locator (URL) 
http://www.trusttelemedicine.com. There were three groups of subjects 
involved in the study. The first group consisted of 18 subjects acting as 
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patients that simulated interactions with clinicians, 18 subjects acting as 
clinicians interacting with patients, and 18 subjects acting as clinicians 
interacting with clinicians. Each simulator contained a simulated 
telemedicine application that allowed for examination of the framework 
that was designed. 
h. A survey was developed to validate diabetes simulators (Appendix C). 
i. Medical experts were surveyed to validate diabetes simulators. 
j. A Web-based telemedicine simulator was developed based upon the 
results of Survey 1 (Appendix B) and Survey 2 (Appendix C): 
i. Macromedia Studio CS4 as design platform 
ii. Patient-to-Clinician view (Simulator 1) 
iii. Clinician-to-Patient view (Simulator 2) 
iv. Clinician-to-Clinician view (Simulator 3) 
k. The 54 subjects were randomized into the patient group or the clinician 
group. 
i. Clinicians were limited to the following professions: 
1. Medical Doctor (MD)  
2. Doctor of Osteopathic Medicine (DO) 
3. Podiatry (DPM) 
4. Psychology (PhD/PsyD) 
5. Pharmacy (PharmD/RPh) 
6. Physician Assistant (PA-C) 
7. Nurse Practitioner (NP) 
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8. Certified Diabetic Educator (CDE) 
l. Validated trust dynamics were incorporated into the simulators based upon 
Survey 1 results. Trust dynamic groupings helped to isolate what 
dynamics play key roles in the formation of trust. Each trust dynamic held 
the same weighting and each simulator had a certain percentage of the 
trust dynamics removed consistent with all simulators of a similar 
dynamic grouping (i.e., simulator 1.75 was consistent with 2.75 and 3.75). 
Classifications were used to isolate each group; Simulator 1, Simulator 2, 
and Simulator 3 were used to classify the interaction category of Patient-
to-Clinician, Clinician-to-Patient, and Clinician-to-Clinician, respectively. 
To further identify and classify the categories, each simulator held a trust 
dynamic number which identifies the percentage of trust dynamics that 
were included in the simulator. Therefore, Simulator 1.100 signified that 
the subject interacted with the Patient-to-Clinician simulator with 100% of 
the trust dynamics included. Simulator 2.50 signified the Clinician-to-
Patient simulator with 50% of the trust dynamics included. Ergo, each 
simulator had four subsections that was used to interact with the users: 
i. Patients were categorized into the following trust dynamic 
groupings, representing Patient-to-Clinician interactions 
(Simulator 1): 
1. 100% of trust dynamics – Simulator 1.100 
2. 75% of trust dynamics – Simulator 1.75 
3. 50% of trust dynamics – Simulator 1.50 
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4. 25% of trust dynamics – Simulator 1.25 
ii. Clinicians were categorized into the following trust dynamic 
groupings, representing Clinician-to-Patient interactions 
(Simulator 2) or Clinician-to-Clinician interactions (Simulator 3): 
1. Clinician-to-Patient: 
a. 100% of trust dynamics – Simulator 2.100 
b. 75% of trust dynamics – Simulator 2.75 
c. 50% of trust dynamics – Simulator 2.50 
d. 25% of trust dynamics – Simulator 2.25 
2. Clinician-to-Clinician: 
a. 100% of trust dynamics – Simulator 3.100 
b. 75% of trust dynamics – Simulator 3.75 
c. 50% of trust dynamics – Simulator 3.50 
d. 25% of trust dynamics – Simulator 3.25 
m. A small group of pilot testers that included one patient and two clinicians 
were used to conduct a pilot test of the simulators, checking for errors or 
problems. 
n. All study subjects who were patients interacted with the primary simulator 
for their category, Simulator 1.100. This established the baseline for all 
patient users. 
o. All study subjects who were patients were then randomly assigned to 
interact with one of the following secondary simulators: 
i. Simulator 1.75 
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ii. Simulator 1.50 
iii. Simulator 1.25 
p. All study subjects who were clinicians, as described in 3(k(i)), were 
categorized into either Clinician-to-Patient or Clinician-to-Clinician. 
q. All clinicians within each subgroup interacted with the primary simulator 
for their category, Simulator 2.100 or Simulator 3.100, depending on their 
stratification. 
r. All study subjects who were clinicians were then further randomized to 
interact with ONE of the following secondary simulators: 
i. Clinician-to-Patient randomized group 
1. Simulator 2.75 
2. Simulator 2.50 
3. Simulator 2.25 
ii. Clinician-to-Clinician randomized group 
1. Simulator 3.75 
2. Simulator 3.50 
3. Simulator 3.25 
s. Following the simulation exercise, each user was asked to complete a 
questionnaire (Survey 3; Appendix G). Survey 3 was validated by both 
sets of experts (Appendix D). The questionnaire was completed by the 
subject at the end of the simulation. The responses were then used to 
establish the validity of the trust dynamics chosen.  
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t. Analysis of the questionnaires was conducted relative to the completed 
questionnaires at the end of the simulations. The researcher expected to 
see clear distinctions between the various levels of trust dynamics that 
were utilized in the simulators. With the trust dynamics decreasing 
incrementally within the four simulators, a comparison was drawn 
between each user group. The hypotheses were that data indicate a clear 
dissention as the trust dynamics are reduced in number. In other words, 
Simulator 1.25 should have only 25% of the established trust dynamics, 
while Simulator 1.100 (control) held 100%. Simulator 1.100 (control) 
should have a higher score than Simulator 1.75, Simulator 1.50, or 
Simulator 1.25 as they fall into 75%, 50%, and 25% inclusion of trust 
dynamics, respectively. Results from each score should follow a 
corresponding reduction. The research is not simply considering the 
reduction, but rather what is being reduced and the impact that reduction 
had on the user’s perceptions of trust. One of the primary goals will be to 
identify trust dynamics that can become central to the framework for a 
successful telemedicine design.   
u. Data was collected and processed through a statistical based software 
package, SPSS, to analyze the results.  
v. The researcher’s hypothesis were either accepted or rejected. 
Statistical Analysis and Design 
 Statistical methodology details the analyses that were performed on the data that was 
collected through the surveys. This section details the approach and justification for each 
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statistical method that the researcher utilized. Statistical analysis allows for predictions to 
be made relative to the hypotheses that have been put forth (Shortliffe & Cimino, 2006; 
Hill & Lewicki, 2006). The specific statistical approaches that were applied depend on 
numerous factors, including sample size, research design, survey questions, data types, 
variable type, and quality of data.  
 Appendix H details the statistical approach for sample size and related calculations. 
The sample size of three groups of 18 users each requires specific statistical tools in order 
to quantify the data in a reliable form. The remainder of this section will outline and 
justify the statistical approach to the set of data collected. 
 In general, the following statistical methods will be applied to the data: 
1. Descriptive Statistics 
2. Correlations and regressions 
3. Differences 
4. Risks and odds 
Descriptive Statistics were utilized to form foundations such as counts (frequency), 
proportions (percentages), measures of central tendency (mean, median, and mode), and 
measures of variation (range and standard deviation) (Shortliffe & Cimino, 2006; Hill & 
Lewicki, 2006). 
 Correlation analyses focused on the relationships found in the data. The researcher 
compared several types of data such as patient’s level of trust in reference to the medical 
information presented. This may prove quite different for users who interact with the 
75% group versus the 25% group. There may also be distinctions between groups, such 
as Clinician-to-Clinician versus the Clinician-to-Patient group. These correlations and 
58 
 
 
  
regressions were analyzed by rank-order correlation and Pearson product-moment 
correlations. Rank-order was used on collected data where subjects had indicated a 
preference or selection from smallest to largest, lowest to highest, and so on. Ranking 
was key to data that was highly subjective in nature to which the researcher cannot apply 
specific and measurable variables, but can judge the respondent’s perspective or view of 
the situation. Additionally, ranking data forced the respondents to decide based on equal 
weighting such as highest to lowest, or least to most, thus allowing a single value to be 
applied to the variable from that subject’s perspective (Shortliffe & Cimino, 2006; Hill & 
Lewicki, 2006). 
 This research examined the role of trust in telemedicine, which carries with it a great 
deal of subjective interpretations by the subject. Subjective data presents challenges in 
evaluating the qualitative and quantitative data that was collected by the respondents.  
 Regression analysis was applied to the collected data in order to predict outcomes of 
future events based on the results of the survey analysis. Regression analysis was a key 
component of this research, as it was focused on the development of a successful 
framework in telemedicine. The framework was based on the regression analysis of the 
data collected. Multiple regression analysis techniques were employed in order to 
consider numerous predictive values that arise from the data collected. Predictive values 
included age, income, study group, education, data layout, form, function, or other 
characteristics associated with the simulators or subjects (Shortliffe & Cimino, 2006; Hill 
& Lewicki, 2006).  
 Another area of statistical analysis to be considered was the difference in outcomes 
between the groups. Perhaps one group of respondents had a marked improvement in the 
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trustworthiness of the simulators. In order to analyze and draw upon the distinctions of 
the groups, the statistical methods of Chi-Squared, Mann-Whitney U Tests, and ANOVA 
were applied to the data (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006).  
 Chi-Squared techniques are used on categorical data such as counts, true-false, male-
female, or normal lab values versus abnormal lab values. Based on the sample size of less 
than 20 subjects per group, a t test cannot be performed on the data. Therefore, the 
researcher applied Mann-Whitney U Tests. Mann-Whitney U Tests (also known as 
Wilcoxon rank sum) allowed the researcher to examine and compare two groups of less 
than 20 subjects; it is a test of equality of medians. Analysis of Variance (ANOVA) tests 
allowed the researcher to examine the group means or averages, testing averages or 
means of two or more groups. 
 Risks and odds were used to examine the predictive outcome of a particular approach 
or survey topic. This analysis was applied to predict how telemedicine can be designed to 
offer the best approach based on patients’ viewpoints, clinicians’ needs or demands, and 
to find the independent values that are reflective of the needs of each group. Analyzing 
data in this way afforded the researcher significant insight into the successful design 
elements of telemedicine.  
 Each of these statistical tools helped to forge a deep understanding of the trust 
dynamics found in a telemedicine system. By analyzing the key components and drawing 
distinct and predictable outcomes based on the variables collected, the researcher was 
then able to identify the key aspects that were utilized in the development of the 
framework.  
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 Additional analysis of the collected data also pointed to previously unidentified 
information that may be beneficial to either this researcher or future research. The 
researcher analyzed the data from numerous perspectives and examined the collected data 
for other trends or comparative relationships. 
 The researcher also paid particular attention to the statistical significance of analysis 
of the data. In order to either accept or reject the null hypothesis, the researcher utilized a 
statistical significance of p< 0.05, or a probability of no more than 5 times out of 100, 
that the difference in the data occurred by chance and the researcher incorrectly rejected 
the null hypothesis.  
 Incorrectly rejecting a true null hypothesis (Type I Error) or incorrectly accepting a 
false null hypothesis (Type II Error) may have a small probability of existing, yet it must 
be acknowledged and recognized. The researcher paid particular attention to the 
formation and possible occurrence of these types of errors. In addition to a p-value of 
<0.05, the researcher utilized a confidence interval of 95%, signifying that the results 
obtained are confidently assured to be accurate 95% of the time.  All statistical analysis 
was conducted using SPSS Statistical Software, version 16.0.    
Tools 
The researcher utilized the Internet to create and deliver the simulations within 
this research. Web site resources were designed and developed using Adobe Creative 
Suite 3 (CS4) Master Collection. Adobe is a leading provider of high end Web and 
Internet design software and platforms. Specifically, Adobe InDesign CS4, Adobe 
Photoshop CS4 Extended, Adobe Illustrator CS4, Adobe Acrobat 9 Pro, Adobe Flash 
CS4, Adobe Dreamweaver CS4, Adobe Fireworks CS4, Adobe Contribute CS4, Adobe 
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ColdFusion CS4, Adobe After Effects CS4, Adobe Premier Pro CS4, Adobe Soundbooth 
CS4, Adobe Encore CS4, Adobe OnLocation CS4, and Adobe Director CS4 was 
employed. PHP 5.0 was utilized as the server-side programming language and JavaScript 
1.8 was utilized as the client-side programming language. Microsoft Office 2003, 
Standard Edition, was utilized as well, which includes Word 2003 (word processor) and 
Excel 2003 (statistical/spreadsheet). Microsoft Visio 2003 (project workflow) and 
Microsoft Project 2000 (project management) software were also utilized. MySQL 5.1 
was utilized as the primary database management tool. Limesurvey was utilized as the 
survey presentation tool. SPSS Graduate Pack 16.0 served as the statistical processing 
software. Finally, Biblioscape Professional was utilized as the bibliographic and citation 
tool.  
Furthermore, the researcher utilized a web host company to manage the 
applications, surveys, and questionnaires. Aplus.net provided hosting of the Internet site. 
The domain name www.trusttelemedicine.com housed the surveys, questionnaires, Web 
applications, and simulators containing established elements of the trust frameworks. 
Simulator 1 (control) contained 100% of the trust dynamics, a second contained 75%, a 
third contained 50%, and a fourth contained 25% of the established trust dynamics. The 
researcher will maintain both the domain name and hosting through the date December 
31, 2011 at a minimum. 
Experts 
 
 The following experts offered assistance in relation to this research, specifically in 
validating its approach and foundations. It was essential to establish the needs from a 
clinical perspective as well as a technical perspective. Experts were selected from various 
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fields of medicine including endocrinology, cardiology, pharmacology, and psychology. 
In addition, experts from the fields of human computer interaction, trust dynamics, and 
persuasive computing were also utilized to support the research efforts. They were able to 
provide guidance in the formation of research methodology, statistical design, simulation 
design, surveys, questionnaires, and framework design.  
Table 1: Experts Who Validated Research Methodology 
Robert Cohen, PAC 
Cardiovascular Disease and Diabetes 
Medical and Trust Expert 
Astellas Pharma US, Inc. 
New York, NY 
Rory Hachamovich, MD, MSc 
Nuclear Cardiologist 
Medical Expert 
Cleveland Clinic 
Cleveland, OH  
 
Lorraine Beck, PhD 
Clinical Psychologist 
Trust and Relationship Expert 
La Jolla, CA 
 
Silvia Novelli, PhD 
Endocrinologist 
Medical and Trust Expert 
Astellas Pharma US, Inc. 
Napa, CA 
 
Delilah Huesling, PhD 
Bioengineering/Cardiac Function/Diabetes 
Medical and Trust Expert 
Astellas Pharma US, Inc. 
St. Louis, MO 
Patty Burkhardt, PharmD 
Clinical Pharmacist 
Medical Expert 
Astellas Pharma US, Inc 
Philadelphia, PA 
 
Sue Miller, PharmD 
Clinical Pharmacist 
Medical Expert 
Astellas Pharma US, Inc. 
Portland, OR 
 
Julie Greely, PharmD 
Clinical Pharmacist 
Medical Expert 
Astellas Pharma Global Development 
Omaha, NE 
Janea McClain, PhD 
Medical and Trust Expert 
Astellas Pharma Global Development 
Baltimore, MD 
 
  
Kalpesh Patel, PharmD 
Clinical Pharmacist 
Medical and Trust Expert 
Astellas Pharma Global Development 
Houston, TX 
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Summary of Methodology 
 
The methodology of this study examined trust by considering the communication 
variables of three separate lines of communication. The first line was communication 
between patient and clinician; the second line was between the clinician and the patient; 
and the third line was between the clinician and clinician. These are typical lines of 
communication in a medical setting. The patient seeks the advice of a clinician, the 
clinician gives advice to the patient, and the clinician seeks advice from other clinicians. 
By examining the trust dynamics between these lines of communication, the researcher 
hoped to gain insight into the dynamics that promote trust.  
The study was conducted with 18 subjects in the Patient-to-Clinician role, 18 subjects 
in the Clinician-to-Patient role, and 18 subjects in the Clinician-to-Clinician role. The 
communication occurred in a simulated online environment and did not actually occur 
between subjects. 
The simulator utilized Markov Chains in order to determine the outcome of the 
treatment recommendations, lab tests, patient involvement, exercise, and dietary habits 
(Shortliffe & Cimino, 2006). Markov Chains are used extensively as decision support 
tools to help determine the outcomes given a certain set of data. 
All subjects interacted with a simulator that had 100% of the trust dynamics that had 
been established. Additionally, each group of 18 subjects was further randomized into 
three subgroups. The first subgroup interacted with a simulator that had 75%, randomly 
generated, of the trust dynamics identified. The second and third subgroups had 50% and 
25%, randomly generated, of the trust dynamics identified, respectively. Those subjects 
in each category of 75%, 50%, and 25% had random generation of those percentages of 
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trust dynamics which will be maintained throughout the simulator exercise. The simulator 
tracked the random assignment of trust dynamics in order to isolate results of the 
psychometric data. 
A pilot test was performed with a small set of users, one patient and two clinicians, to 
verify any problems with the simulator. This test also ensured that links were working 
correctly and that the graphic display of the Markov Chains was functionally correct. The 
pilot testers also ensured that the survey questionnaires were in working order. The 
researcher verified that the survey results were being captured and secured. 
It was the intention of the researcher to draw distinct conclusions about the trust 
dynamics between all of the subgroups involved in the study. Once the data had been 
collected, statistical analysis guided the researcher to either accept or reject the 
hypotheses of this research.  
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Chapter 4 
Results 
Overview 
 This chapter reports and details the results of the study outlined in Chapter 3, the 
methodology section. The chapter is broken down into five main sections that specify 
particular aspects of the research. Section one focuses on the best practices and approach 
chosen by the researcher. Section two focuses on the results of the interactions of the 
Subject Matter Experts (SME) and reviews the results of the surveys, development of the 
trust framework, as well as outlining the limitations chosen for this research. Section 
three reviews the design, development, and construction of the simulators and each 
participant’s survey. The fourth section of this chapter provides an analysis of the data 
collected from the total number of participants’ surveys, while the fifth section discusses 
these findings. 
Current Best Practices of Telemedicine 
 
 The researcher relied on several approaches to determine the best practices in the 
design of telemedicine applications, these included attending the American Telemedicine 
Association conferences (ATA 2009: 14th Annual International Meeting & Exposition, 
April 6-8, 2009, Las Vegas, NV), the American Medical Informatics Association 
conference (AMIA 2009: Biomedical and Health Informatics: From Foundation to 
Applications to Policy, November 14-18, 2009, San Francisco, CA). Attending these 
meetings allowed the researcher to gain insights into current best practices in 
telemedicine systems from both a research perspective, by attending scientific sessions, 
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as well as developer perspective, by viewing demonstrations of exhibitors. The scientific 
sessions at these conferences showed the current state of research in the field, while 
exhibitions by vendors showed the current best practices of companies marketing 
telemedicine applications. 
In an effort to develop a well-rounded and comprehensive simulated environment, the 
researcher noted the best practices presented at these important meetings. Those which 
were relevant to the subset of activities that the researcher wished to examine were 
incorporated into the design of the simulator. 
 One common element in the development and implementation of the telemedicine 
systems, employed in the majority of demonstrations by vendors was the use of a patient 
case study to demonstrate the utility of the software. A case study represents the 
presentation of a patient with a specific disease or illness, such as diabetes, which was 
typical or characteristic of what a clinician encounter. The case study is used to 
demonstrate the functionality, capabilities, and usefulness of the telemedicine system. 
The case study approach also allows the system to be fully realized without the hurdles 
and time consuming details of a dynamic system. The use of a case study limited the 
functionality and capabilities of the simulator; however it also allowed trust dynamics, 
the focus of this research, to be extensively explored while limiting the time demands 
placed on participants in the study. The researcher set a soft time limit of 30 minutes to 
complete the study, including time to interact with the simulators and completing the 
survey. 
 Additionally, it is customary in medical education and training to utilize the case study 
approach. Familiarity with the case study approach may account for the researcher’s 
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observations that clinicians at the conferences appreciated and adapted well to case 
studies presented via telemedicine systems. These demonstrations allowed clinicians to 
view the features and functionality of the system. It also allowed the clinicians to see the 
medical content and disease state management aspects as well as the patient information 
that was provided. 
 Another best practice was the provision of system security. It was also noted that the 
telemedicine systems used a variety of algorithms to manage security. Although most 
utilized Secure Sockets Layer (SSL), there were others which utilized a secure key, or 
other security device, as well as username and password protection. In many cases, the 
researcher observed that security was not necessarily obvious to the attendees at the 
conference: however, it was mentioned by the company representatives. 
 It was also noted that many telemedicine operators utilized a variety of medical 
resources within the systems. These include RSS feeds of medical information, adoption 
of medical or disease specific association treatment guidelines, published algorithms for 
procedures or therapy, as well as other sources for evidence-based medicine. The 
majority of these features were readily noted by the attendees and the researcher had an 
opportunity to observe users’ positive responses to these features. They were clearly a 
strong selling point. 
 Best practices demonstrated that telemedicine providers are utilizing a variety of 
methods to interact with patients or clinicians. In order to develop the framework and 
create the simulators, the researcher selected several specific elements of current best 
practices used by telemedicine providers to incorporate into this simulated system. As do 
most providers, the researcher utilized a case study model in the simulated telemedicine 
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system. The case will specifically be the treatment of diabetes, a disease affecting a large 
number of people and increasing worldwide as noted earlier in this work. The case 
presented to participants was validated by the medical subject matter experts. In addition, 
the researcher utilized published guidelines and algorithms related to the treatment of 
diabetes (Appendix J; Appendix K), providing best practices methodologies from leading 
medical authorities. 
Design Elements Model 
As with telemedicine best practices, telemedicine design models were collected while 
the researcher attended the ATA and the AMIA conference. Best practices in the field of 
telemedicine appeared to maintain a variety of approaches; however, one theme that 
seemed to be consistent was the similarities to medical charts, which contain a plethora of 
data on a single form. The approach that was utilized for the simulators combined a great 
deal of detailed medical information on one continuous form per patient, separated into 
appropriate sections, representing the patient history and disease state management. This 
format allowed the vendor to display the full capabilities for the system without concern 
of patient confidentiality. 
Design also focused on the attributes of combining the medical information in a 
simple flow based process. In order to present the information in a consistent and applied 
manner, the researcher formulated the contents into logical groups, highlighting each 
group with a specific color (Appendix N). This design was a noted feature in several of 
the systems studied. Having viewed numerous systems, the researcher incorporated 
common elements in order to enhance the system design and to isolate the parameters and 
scope of the simulators (Appendix N). 
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The researcher instructed the participant through each category via the simulator, 
carefully explaining the process so that the presentation of the flow of data was clear and 
concise. The flow of instruction is represented in Appendix L. Color schemes and data 
categories were selected based on similar traits of the information, with the titles of each 
category as follows: Patient Demographic Information, Disease State Management, 
Treatment Options, Goals of Therapy, and Reference Material (Appendix N).  
Simulation Models and Subject Matter Experts 
 The best practices researched for telemedicine, both content and design elements 
derived from current practices of providers and researcher were then used to develop a 
rough framework for the telemedicine trust model. The information was combined with 
the research conducted in Chapter 2, the literature review. In addition, the research 
conducted in Chapter 2 contributed to the framework of the trust model. The model was 
presented to the SME group to be reviewed and validated. 
Three iterations of the trust model were realized by the researcher as the development 
process of the trust model was validated by the SME. The initial trust model attempted to 
capture the baseline aspects that the researcher felt were significantly tied to trust. As 
seen in Figure 2, the first tier of the initial framework considered the formation of trust 
from the individual perspective, which represents the components of trust based on the 
experiences and views of the individual. These elements are comprised of what the 
participant would bring to the table and are not considered attributes that telemedicine 
systems could manipulate.  
The second category is institutional trust. This level represents the trust that a user 
may perceive in the clinician, the institution behind the clinician such as a major hospital 
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or health care system, or the trust the clinician has in the patient. This area represents a 
complex and dynamic system of public opinion and personal perception. The category is 
separated out due to the nature of the institution or clinician, whose reputation may be 
enhanced or reduced by transient events, for example a series of front page headlines 
describing a medical breakthrough or a publicized case of gross negligence by the 
clinician or institution. A positive reputation built up over time builds trust (Josang, 
Ismail, and Boyd, 2007).   
The third category was identified as online behavior which is considered to be a 
function of the user’s comfort level, ability, or history with online systems, health 
information searches, and other factors that could enhance a user’s trust in the system. A 
naïve user may have a difficult time trusting something in an environment such as 
telemedicine if they have no experience with online systems. Conversely, a user who has 
significant online experience may have a greater likelihood, at least initially, to trust the 
system. 
The next tier identified was the medical, privacy, and design components of the 
system. One of the dissertation’s major hypotheses is that the medical content, security, 
privacy, and design would impact the level of trust in the system. This category is unique 
in that it combines elements of the user predisposition to trust as well as the experiences 
of the telemedicine system. In this context however, the researcher is implying that the 
system needs to enhance the trust level through the experiences within the telemedicine 
system. All of these components working together would represent the trust model being 
designed. Figure 2 represents the trust model that was presented to the SMEs. 
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Figure 2: Initial Telemedicine Trust Framework 
 
Feedback from the SME helped to direct the focus of the framework on more specific 
characteristics of trust. The comments indicated that more detail needed to be included in 
the levels of trust and how trust is formed from each perspective. Many of the SMEs 
indicated that clinicians may have a unique perspective as trust is formed. The SME 
feedback helped the researcher focus in on several key components, specifically the 
division between an individual’s predisposition to trust and institutional trust. Within 
these categories another tier was introduced to capture three distinct categories: 
knowledge based trust, calculus based trust, and relational trust. 
Knowledge based trust is comprised of the individual’s predisposition to understand or 
operate in the realm of knowledge or education. Certainly a clinician should have an 
abundance of knowledge about the disease state, but he or she may wish to disseminate 
that knowledge. Some patients are more prone to expect that they will gain knowledge 
from their interactions with the clinicians, while others are simply happy when their 
clinician is not concerned about their condition. There is a great diversity in this area 
within each population; it should be accounted for from a specific approach. A one-size-
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fits-all approach would not be appropriate within the context of knowledge based trust 
design. Systems need to address the great diversity present within the population in order 
to maximize the benefit from this aspect of trust design. 
Calculus based trust is a component of items that add or subtract to the trust model 
that are not necessarily specific, as in a culmination of numerous factors. Calculus based 
approaches consider items that may be outside of the scope of the trust model approach, 
but still may have a significant influence on the trust experienced by the user. It is 
individualistic in nature and therefore is closely tied to the individual predisposition to 
trust. 
The field of medicine is one that is closely tied to the domain of relational trust, which 
is developed between clinician and patient. Some clinicians develop and manage close 
personal relationships with their patients, while others may maintain distance from their 
patients. Patients, on the other hand, may or may not wish to have a close relationship 
with their clinician. The possibilities are as complex and dynamic as they are in other 
sectors of the social network. These aspects are individualistic and distinct and therefore 
the research design attempts to take into account such influence, for example, by asking 
survey questions pertaining to the type of relationship with clinicians the respondent 
prefers. 
The feedback from the SMEs also helped the researcher focus in on the attributes at 
the individual component level of the system. The medical, privacy, and design 
components each carry specific traits that may influence a patient’s or clinician’s overall 
level of trust in a telemedicine application. 
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Consultation with the SMEs helped to clarify some of these nuances, such as 
subcategories of the medical content component, which were further classified as EBM, 
medical content, disease state management, and perceived outcomes of the patient. 
Privacy components were broken down into privacy, security, and Health Insurance 
Portability and Accountability Act (HIPAA) compliance. Design components were 
recognized as page layout, navigation, professional design, and user experience.  
The culmination of all of these dynamics created the level of trust that the user would 
experience through the telemedicine system. These criteria were then resubmitted to the 
SME group, as represented in Figure 3. The SME group again provided strong feedback 
on the content. 
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Figure 3: Adjusted Telemedicine Trust Framework 
 
The SME response was to delve deeper into some of the correlations, which resulted 
in the final version of the framework, as seen in Figure 4. This iteration identified the 
characteristic of User Centric Trust (UCT) and System Centric Trust (SCT), which 
separated out the units that carry unique challenges. UCT is more fluid and dynamic with 
regards to individual user aspects while SCT carries more traditional system attributes. 
Online behavior was one aspect that was the bridge between the two elements. The SME 
group also helped to focus attention on potential bypass or backpropagation of the model, 
meaning that the individual predisposition could move directly to the institutional trust 
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component, bypassing the knowledge, calculus, or relational based trust aspects. This 
may happen when a user perceives the quality of the institution to trump other aspects. 
For example, a user may feel that the institution is so highly reputable that they will not 
question the many aspects that would normally be applicable. However, institutional trust 
can also be backpropagated to the individual propensity. This scenario could be evident if 
the institution suddenly receives positive or negative press such as a user being told that 
Harvard, UCLA, or Cleveland Clinic had developed or were participating in the 
telemedicine project. Certainly front page headlines, whether of medical miracles or 
cases of malpractice, could sway an individual’s predisposition to trust the institution. 
This predisposition is distinct from the individual’s propensity in that these may include 
issues that reside outside of the individual’s control that may influence trust. 
Figure 4 illustrates the final version of the Telemedicine Trust Framework (TTF) as 
validated by the SMEs. Feedback from the experts also indicated several areas that may 
need to be addressed within the simulator models. One such area is the distinction that 
users will vary greatly in terms of their medical or scientific knowledge or aptitude. This 
could prove to be a difficult challenge within a telemedicine system and may be a 
limitation within the simulators due to the scope of the project. Another area pointed out 
by the experts is the degree of agreement among opinions and approaches that are 
established by clinicians in the treatment of a disease such as diabetes. Both of these may 
have been a limitation of the simulators and may be an opportunity for future research as 
they are beyond the scope of this work.  
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Figure 4: Telemedicine Trust Framework 
  
Medicine is not an exact science, which often gives rise to the phrase the ‘practice of 
medicine.’ It is often subjective, with a variety of scientific approaches combined with 
the clinical judgment of the clinician. This creates challenges when attempting to develop 
a system that facilitates the treatment paradigm, as the system may or may not conflict 
with a particular clinician’s view of the best approach. The researcher addressed this 
issue by selecting a number of approaches that are considered best practices in the 
treatment of diabetes, namely algorithms and guidelines developed by American 
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Association of Clinical Endocrinologists/American College of Endocrinology 
(AACE/ACE) as well as EBM of large scale clinical studies. Therefore, a by-the-book 
approach allowed the treatment algorithms to remain consistent within the case study for 
all participants. The trust variables were adjusted accordingly to help determine their 
impact on the user. Considering the small sample size of the study, it was important to 
remain consistent so as not to skew the results. Input and analysis from the subject matter 
experts validated the case study, disease state management, and treatment options 
sections of the framework and developed foundational support for the construction of the 
simulators. 
 This information allowed the development of a diabetes-specific simulator. This was 
coupled with the general telemedicine trust model which was developed to identify the 
clinical information and treatment options of the system. By incorporating disease 
specific information with the general model, the researcher was able to tie the trust model 
into the specifics of this research. The AACE/ACE guidelines are outlined in Appendix J, 
while the EBM model utilized is outlined in Appendix K. Privacy statements, security, 
and HIPAA compliance models were developed from current guidelines as published by 
the American Telemedicine Association and the American Medical Informatics 
Association. The model was validated by three SMEs in the field of diabetes management 
and includes the attributes outlined in Figure 4. 
Simulated Comparative Interactions 
 The end result of developing a general trust framework, consulting with experts and 
organizations on treatment of diabetes mellitus, and combining these two aspects of the 
research, was a series of simulators which presented respondents with detailed 
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information on a specific case of the disease. The clinicians’ simulators presented them 
with a case study of a hypothetical patient, giving detailed information about the patient’s 
demographic characteristics and social history.  
 The case study simulation for the clinician presented detailed, medically relevant 
information about a particular patient, the case study was modified for the participants 
who where acting as patients to provide a more educational approach. During the 
building of the specific diabetes-related model for telemedicine, the researcher found that 
the model was heavily weighted towards diabetes education. Therefore, the model had to 
include a great deal of educational information for the patient. This also served as an 
excellent hybrid between the patient and clinician case study, as the patient simulator 
focused attention on the explanation of the disease.  
Nine simulators plus the three baseline scenarios, for a total of twelve, were developed 
based on the case model. One set was developed for the Clinician-to-Clinician group, one 
set for the Clinician-to-Patient group, and one set for the Patient-to-Clinician group. Each 
group’s simulator had a control simulator which contained 100% of the trust dynamics 
identified the baseline scenario. Each group also had three additional simulators 
developed, one simulator each contained 75%, 50% and 25% of the trust dynamics 
identified.  
Each category of participant viewed the simulator appropriate for their role and which 
contained 100% of the trust dynamics. Next, the participants were randomized to view a 
second simulator containing 75%, 50%, or 25% of the trust dynamics, again appropriate 
to their role in the study. They were asked to take the survey and answer the questions 
based on the viewing of the second simulator.   
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Selection, Stratification, and Randomization Processes 
 The categorization noted above occurred as the participants navigated through the 
simulators. First, respondents were stratified according to (self identified) real-world 
qualifications. The two randomization processes further categorized subjects. The most 
obvious is the distinction between a clinician and a patient, which was chosen as a step 
process conducted by the participant. If the user met the requirements of a clinician, they 
would choose accordingly. If they did not qualify, they were expected to select the 
Patient category. There was not any qualification metrics applied to verify that the user 
made the correct choice, the selection process was user driven. This was characterized in 
Figure 5: 
 
Figure 5: Selection Process of Simulator 
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However, if the user selected the Clinician approach, they could fall into one of two 
categories, Clinician-to-Patient or Clinician-to-Clinician. A formal process was set up to 
manage the stratification of the Clinician. Figure 6 illustrates the user interaction: 
 
 
Figure 6: Stratification Process of Simulator 
 
 The process behind the stratification is database driven. As clinicians self-selected into 
the clinician category, they were then alternately assigned to the Patient-to-Clinician or 
Clinician-to-Clinician interaction group, either patient or clinician. Finally, the 
participants were randomized, within each group, to view the second simulator of 75%, 
50%, or 25% of the trust dynamics. As participants navigated through the study, they 
were presented with the baseline simulator, or 100% of the trust dynamics, and then they 
were presented with the simulator with 75%, 50%, or 25% of the trust dynamics 
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identified depending on their randomly assigned group. This process was accomplished 
via a database model approach. 
Survey Construction 
 Limesurvey, a web-based software tool for survey development, was utilized to 
develop and administer the survey questionnaire to the study participants. Limesurvey 
automatically incorporated a number of database tables in order to record the interaction 
of the participants at the end of the survey.  The database design and layout is found in 
Appendix M. The survey was constructed using triggers on each question that forced a 
response in order to continue. Only data from completed surveys was posted to the 
database. By forcing responses and accepting only completed surveys, the software 
removed any possibility of incomplete responses or missing data. 
Pilot Test and Analysis 
 Prior to the launch of the study, the system was fully tested and analyzed for errors, 
omissions, and issues. A total of four SMEs agreed to test the system and validate the 
results. Minor changes and corrections were made to the system following the input from 
the SMEs.  
Response Rate 
 A total of 55 participants (one more than anticipated in the Patient group) were 
included in the research study. Once each participant group was filled, the database was 
locked to avoid new entries from being included. However, it was noted that an error in 
programming did not lock the entire project out prior to one additional participant 
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completing the survey in the Patient group. Once that was discovered, the database was 
locked and the study closed.  
The response rate for the Patient group was rapidly filled, while the Clinician group 
proved to be more challenging. Friends and family responded quickly with the majority 
filling the patient groups, therefore few attempts at recruiting were needed to fill the 
patient group of the study. This fact could also introduce bias based on each participant’s 
relationship to the researcher and the resulting skew in demographic characteristics. The 
clinician group was more difficult to fill, and required numerous approaches including 
posting to user groups at the American Medical Informatics Association and American 
Telemedicine Association, as well as posting messages at electronic boards of several 
southern California medical centers (UCSD Medical Center, UCLA Medical Center, and 
Loma Linda Medical Center). The researcher also found clinician-participants via work 
colleague networks. Ultimately, the researcher managed to acquire the necessary 
participation to complete the study. 
Demographics of Respondents 
 Table 2 describes the demographics of the participants within each group to which 
they were randomized and/or stratified. The first section of the table represents the 
computer literacy of the participants. The majority of the participants in the clinician 
group indicated that they were either computer proficient or sufficient, with only 17% of 
the participants in the Clinician-to-Patient group indicating that they were computer 
experts.  
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Table 2: Demographic Data 
 
Main Group                                                              Frequency      Percent        Cumulative % 
How would you rank your computer/online literacy? 
C2C Computer/Online Proficient 14 77.8 77.8
Computer/Online Sufficient 4 22.2 100.0
C2P Computer/Online Expert 3 16.7 16.7
Computer/Online Proficient 12 66.7 83.3
Computer/Online Sufficient 3 16.7 100.0
P2C Computer/Online Expert 4 21.1 21.1
Computer/Online Proficient 9 47.4 68.4
Computer/Online Sufficient 2 10.5 78.9
Computer/Online Novice 4 21.1 100.0
Gender? 
C2C Male 9 50.0 50.0
Female 9 50.0 100.0
C2P Male 6 33.3 33.3
Female 12 66.7 100.0
P2C Male 5 26.3 26.3
Female 14 73.7 100.0
What is your age? 
C2C 18-25 3 16.7 16.7
26-35 3 16.7 33.3
36-45 1 5.6 38.9
46-55 7 38.9 77.8
56-65 3 16.7 94.4
>65 1 5.6 100.0
C2P 26-35 3 16.7 16.7
36-45 6 33.3 50.0
46-55 5 27.8 77.8
56-65 2 11.1 88.9
>65 2 11.1 100.0
P2C 18-25 3 15.8 15.8
26-35 1 5.3 21.1
36-45 8 42.1 63.2
46-55 2 10.5 73.7
56-65 2 10.5 84.2
>65 3 15.8 100.0
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Table 2: Continued 
Main Group                                                             Frequency      Percent       Cumulative %
Education (highest level attained): 
C2C MBA 1 5.6 5.6
Clinical Healthcare Provider 13 72.2 77.8
Doctorate - Life Science  4 22.2 100.0
C2P Bachelors Degree/Adv Trade School 2 11.1 11.1
Clinical Healthcare Provider  7 38.9 50.0
Doctorate - Life Science  8 44.4 94.4
Doctorate - Non Life Science  1 5.6 100.0
P2C High School Graduate 2 10.5 10.5
Some College 3 15.8 26.3
Associates Degree/Trade School 1 5.3 31.6
Bachelors Degree/Adv Trade School 6 31.6 63.2
Masters Degree 3 15.8 78.9
MBA 1 5.3 84.2
Non Clinical Professional  1 5.3 89.5
Doctorate - Life Science 1 5.3 94.7
Doctorate - Non Life Science 1 5.3 100.0
Household Income Annually (optional): 
C2C 0 6 33.3 33.3
$75,000 - $99,999 1 5.6 38.9
$100,000 - $124,999 4 22.2 61.1
$125,000 - 149,999 1 5.6 66.7
$150,000 - $174,999 3 16.7 83.3
$175,000 - $199,999 3 16.7 100.0
C2P 0 4 22.2 22.2
$100,000 - $124,999 1 5.6 27.8
$125,000 - 149,999 6 33.3 61.1
$150,000 - $174,999 3 16.7 77.8
$175,000 - $199,999 4 22.2 100.0
 
P2C 
0 3 15.8 15.8
Less than $25,000 1 5.3 21.1
$25,000 - $49,999 1 5.3 26.3
$50,000 - $74999 1 5.3 31.6
$75,000 - $99,999 2 10.5 42.1
$100,000 - $124,999 1 5.3 47.4
$125,000 - 149,999 2 10.5 57.9
$150,000 - $174,999 4 21.1 78.9
$175,000 - $199,999 4 21.1 100.0
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The patient group indicated a much wider range of computer literacy, with 68.4% of 
the respondents indicating computer literacy at the proficient or expert level. 
Interestingly, 21% also indicated that they were computer novices.  
 The next section represents gender, which surprisingly carried a disproportionate 
amount of females relative to the general population in both the Clinician-to-Patient and 
the Patient-to-Clinician; it was evenly split for the Clinician-to-Clinician. Could this 
possibly represent a higher degree of adoption or interest in telemedicine in females 
versus males? Although it is beyond the scope of this study, it would be interesting for 
future research to examine the trust dynamics and adoption rates based on gender 
(Shortliffe & Cimino, 2006; Hill & Lewicki, 2006).  
 In terms of age, the researcher found that the majority of participants fell into the 35-
55 year old group across all categories. However, it should be noted that each participant 
group produced responses from all age groups, helping to balance out the research in 
terms of age.  
 Education was the next category and, as expected, produced the most educated group 
in the clinician categories, with all but one clinician represented by clinical degrees or 
doctorates in life science. The patient group represented a much greater degree of 
variability in education, however 68.4% still reported that they had a bachelors degree or 
higher. These data indicate that there are a large number of highly educated participants 
in this study. 
Income was an optional item that had mixed responses. Of those clinicians who 
responded, the vast majority of clinicians (61.2% of the Clinician-to-Clinician group and 
77.8% of the Clinician-to-Patient) reported greater than $100,000 in annual income. This 
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is most likely tied to age and education (Shortliffe & Cimino, 2006; Hill & Lewicki, 
2006). The patient group was much more diverse and represented a one third split 
between incomes less than $100,000, one third between $100,000 and $150,000, and one 
third greater than $150,000. 
Non-Response Bias Testing 
 Since all users were required to complete the survey in its entirety, the researcher did 
not need to calculate non-response bias testing. The design of the system forced all users 
to complete the survey, and all accompanying questions, prior to submitting the survey. 
Failure to complete all categories would simply dump the data and not post it to the 
appropriate databases. However, data was collected to determine how many participants 
accessed the system and began the process. The difference between total unique users 
who accessed the system to begin the study and the total users who actually completed 
the study gave the researcher an idea of the overall response rate. A total of 98 
participants accessed the system during the trial period, with 55 subjects completing the 
process. This introduces a bias towards participants who have the wherewithal to 
complete the study, or those who were interested in the research (Shortliffe & Cimino, 
2006; Hill & Lewicki, 2006). Feedback from some respondents indicated that the 
simulators and accompanying survey were long and rather involved. Future researchers 
should consider the time constraints that are involved for the participants. 
Descriptive Statistics 
The majority of variables that were utilized in this research were built upon a five-
point scale. Those that were not based on this scale were adjusted to correlate with the 
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five-point scale (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006). Skewness measures 
the symmetry of the distribution of the data. If the resultant data were to fall outside of 
the normal range of +1 or -1, then the data is said to have substantial skewness. Table 3 
represents the skewness values for each of the derived variables within the study, 
categorized by group (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006). 
  None of the results indicated significant skewness in the variables in relation to the 
populations of the study groups. It should be noted that results are reported for each 
group, with C2C representing Clinician-to-Clinician, C2P representing Clinician-to-
Patient, and P2C representing Patient-to-Clinician. 
Table 3: Skewness Table 
Statisticsa 
Variable C2C 
Skewness 
C2P  
Skewness 
P2C  
Skewness 
Trust_Score -.277 -.144 -.170 
Health_Dynamics_Medical_Collection_
Data 
-.400 -.389 -.110 
Design_Elements_Data -.250 -.601 -.190 
Outcomes_Information -.435 -.407 -.093 
Relationship_Information -.177 -.054 -.170 
Propen_Trust -.800 -.247 -.459 
Propensity_Patient_Clinician_Interactio
ns_UP 
.409 .316 .247 
a. Main Groups = C2C (clinician-clinician) C2P (clinician-patient) P2C (patient-clinician) 
 
 A correlation matrix was established to estimate the degree of relatedness between the 
variables studied (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006). Table 4 indicates 
the relationship between the dependent and independent variables, as calculated per 
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group and as identified for the hypothesis testing. All variables indicated a direct 
correlation to the dependent variable at a level of p<.01.  
Table 4: Correlation Matrix 
Main Group 
Trust 
Score 
Health 
Dynmx
Design 
Dynmx 
Diabetes 
Resource
Page 
Layout 
Nav/Design 
Elements 
Patient Clinician 
Interactions 
C
2
C 
Trust 
Score 
Pearson 
Correlation 
1 .880** .986** .847** .867** .870** .852**
Health 
Dynamics 
Pearson 
Correlation 
.880** 1 .853** .787** .775** .756** .803**
Design 
Dynamics 
Pearson 
Correlation 
.986** .853** 1 .841** .859** .868** .802**
DiabetesRe
source 
Pearson 
Correlation 
.847** .787** .841** 1 .648** .631** .642**
Page Layout Pearson 
Correlation 
.867** .775** .859** .648** 1 .950** .869**
Navigation 
Design 
Pearson 
Correlation 
.870** .756** .868** .631** .950** 1 .839**
Patient 
Clinician 
Pearson 
Correlation 
.852** .803** .802** .642** .869** .839** 1
C
2
P 
Trust Score Pearson 
Correlation 
1 .916** .951** .746** .746** .785** .918**
Health 
Dynamics 
Pearson 
Correlation 
.916** 1 .866** .850** .727** .756** .842**
Design 
Dynamics 
Pearson 
Correlation 
.951** .866** 1 .735** .714** .792** .873**
Diabetes 
Resources 
Pearson 
Correlation 
.746** .850** .735** 1 .569* .556* .617**
Page Layout Pearson 
Correlation 
.746** .727** .714** .569* 1 .839** .739**
Navigation 
Design 
Pearson 
Correlation 
.785** .756** .792** .556* .839** 1 .835**
Patient/Clin 
Inter 
Pearson 
Correlation 
.918** .842** .873** .617** .739** .835** 1
P
2
C 
Trust Score Pearson 
Correlation 
1 .729** .957** .745** .624** .661** .738**
Health 
Dynamics 
Pearson 
Correlation 
.729** 1 .725** .843** .433 .526* .629**
Design 
Dynamics 
Pearson 
Correlation 
.957** .725** 1 .683** .649** .644** .706**
Diabetes 
Resources 
Pearson 
Correlation 
.745** .843** .683** 1 .429 .494* .506*
Page Layout Pearson 
Correlation 
.624** .433 .649** .429 1 .726** .511*
Nav/Design 
Elements 
Pearson 
Correlation 
.661** .526* .644** .494* .726** 1 .459*
Patient/ Clin 
Interactions 
Pearson 
Correlation 
.738** .629** .706** .506* .511* .459* 1
*Correlation is significant at the 0.05 level (2-tailed); **Correlation is significant at the 0.01 level (2-tailed).  
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Control Variables 
 The researcher included two control variables within the study. The purpose of a 
control variable is to establish a variable that will affect the dependent variable (Shortliffe 
& Cimino, 2006; Hill & Lewicki, 2006). Strong research characteristics demand the use 
of a control variable for the study to be robust (Shortliffe & Cimino, 2006; Hill & 
Lewicki, 2006). The goal of the researcher was to avoid using superfluous control 
variables within each subject group and to examine the relationships between the 
dependent and independent variables. The researcher categorized the propensity to trust 
as High, Medium, and Low split evenly across the five point scale (Shortliffe & Cimino, 
2006; Hill & Lewicki, 2006). Table 5 represents the ANOVA of the propensity to trust 
variable and the patient clinician interaction variable compared to the trust variable. 
Table 5 indicates there is a division between propensity to trust, a value which is 
statistically significant and patient clinician interaction, a value which is not statistically 
significant. Propensity to trust does have a significant impact on trust across all groups, 
while patient clinician interaction does not produce any significance across all groups. 
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Table 5: Control Variables impact on trust 
ANOVA 
Main Group 
Sum of 
Squares df 
Mean 
Square F Sig. 
C2C Propensity to 
Trust 
Between Groups 6.366 14 .455 14.197 .002
Within Groups .325 3 .108   
Total 6.691 17    
Propensity 
Patient Clinician 
Interactions 
Between Groups 2.893 14 .207 .209 .983
Within Groups 2.973 3 .991   
Total 5.866 17    
C2P Propensity to 
Trust 
Between Groups 3.649 15 .243 18.297 .001
Within Groups 1.640 2 .820   
Total 5.289 17    
Propensity 
Patient Clinician 
Interactions 
Between Groups 1.924 15 .128 1.239 .535
Within Groups .207 2 .104   
Total 2.131 17    
P2C Propensity to 
Trust 
Between Groups 3.223 12 .269 13.667 .002
Within Groups .118 6 .020   
Total 3.341 18    
Propensity 
Patient Clinician 
Interactions 
Between Groups 3.352 12 .279 1.077 .492
Within Groups 1.557 6 .259   
Total 4.909 18    
 
Propensity to Trust 
 Propensity to trust is the first control variable that the researcher identified. The value 
of the variable was generated by combining several responses from the survey by each 
participant (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006). The calculation is based 
on the mean scoring of a percentage assigned by the researcher. Table 6 illustrates the 
dimensions of the propensity to trust variable. The variable assigns a baseline value in 
order to measure the participant’s propensity to trust other people, online medical data, 
clinicians, institutions, or organizations (Shortliffe & Cimino, 2006; Hill & Lewicki, 
2006).  
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Table 6: Propensity to Trust Questions (1-Strongly Disagree to 5-Strongly Agree) 
 
 
 
 
 
 
The calculation for an individual participant is established as a sum of a percentage of 
each category. The calculation for the group is the mean of those sums.  
The second category of control variables is the patient-clinician interactions. This 
value represents the baseline measure for the characteristics that measure the relational 
propensity between patient and clinician (Shortliffe & Cimino, 2006; Hill & Lewicki, 
2006). It does this by analyzing the key attributes associated with the survey that deal 
with a user’s predisposition to patient-clinician interactions. The culmination of questions 
is represented in Table 7 and includes the statistical analysis of the set per group.  
 
Table 7: Attitude Towards Patient Clinician Interactions (1-Strongly Disagree to 5-
Strongly Agree) 
13. How often do you visit a doctor? 
14. How would you rate your general health? 
15. In the last 6 months, how often have you sought medical information online? 
16. How would you rate your online medical search experience? 
17. How would you rate the quality of medical information online? 
18. Do you have any future intentions of conducting online medical searches? 
19. In general, are you concerned about your personal privacy of medical information online? 
20. In communicating medical information online, are you concerned that the communication may not be 
received or communicated correctly?  
 
7. Do you consider yourself a trusting person? 
8. Do you trust until proven otherwise? 
9. Do you consider yourself to have trust issues? 
10. Do you generally believe in others? 
11. In general, do you have trust when you are using the Internet? 
12. Do you have trust in online medical information? 
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 Based upon the information in Table 6 and Table 7, a score calculation was performed 
for each group within each control variable. The calculated scores are identified in Table 
8, broken down by group. 
 
Table 8: Calculated Score for Control Variables 
 
 
Dependent Variable 
 The dependent variable is identified as the trust score. It is a calculated variable based 
upon a number of survey questions that were directly related to trust. Table 9 provides a 
review of the trust related questions that were used to create the trust score. The trust 
score allows the researcher to categorize and analyze the results of the surveys in a 
uniform pattern. Changes that occur within the dependent variables provide the 
foundation of what is being examined by this research. The trust score is used to 
determine the influence that any one category, or group of categories, has on the 
participant.  
 By establishing the trust score, it allows the researcher to compare the results of each 
survey to the other critical areas being examined. It was expected that the trust score 
would vary based on the trust dynamics involved, however, the trust dynamics playing 
the most significant role were yet to be determined.  
 
Main Group 
Propensity to 
Trust 
Attitude Towards 
Patient Clinician 
Interactions 
C2C Mean 3.2222 3.1664
Std. Deviation .62737 .58742
C2P Mean 3.3056 3.3416
Std. Deviation .55780 .35406
P2C Mean 3.4184 3.1896
Std. Deviation .43083 .52221
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Table 9: Survey Questions included in calculating Trust Score (1-Strongly Disagree 
to 5-Strongly Agree) 
Statistics 
26. I trust the diabetes resources that were provided? 
28. The dietary information was trustworthy? 
31. I trust the exercise information that was provided: 
38. I intend to seek medical information from other sources online to validate information received on this 
site. 
39. I feel comfortable asking the Clinician (or Patient) for further explanation on (or understanding of) the 
medical information. 
40. The institution behind the telemedicine site had a high degree of ethics and morals. 
41. I felt a personal connection with the person with whom I was interacting online. 
42. With regards to this site, I trusted the flow of information. 
44. I felt a great distance between myself and the person with whom I interacted. 
46. I trust the person on the other end of the conversation. 
47. I trust that private medical information would be managed appropriately and carefully to prevent 
unauthorized access by others? 
50. The Clinician (Patient) with whom you interacted had a high degree of ethics and morals. 
51. The Clinician (Patient) was dependable and reliable. 
61. Overall, the contents of the site support feelings of trust: 
62. The images and graphics contained on the site instill a sense of purpose and trust: 
70. How would you estimate your level of trust with telemedicine based on your experience with this site?
 
Independent Variables 
 Independent variables were categorized into four groups in order to capture the 
necessary relationships between the survey and the research hypotheses (Shortliffe & 
Cimino, 2006; Hill & Lewicki, 2006). The first category captured was Health Dynamics 
and the second is Design Elements, both of which are calculated variables, each based on 
its own group of related questions within the survey. Disease State Management data and 
Relational data are subsets of the Health Dynamics data that are more specific to those 
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categories. Medical information is represented by the categories of Disease State 
Management data and Relational data, which are subsets of the Health Dynamics data. 
 One of the main focal points of this research was based on the medical information 
and how it was interpreted. Table 10 represents the items that were captured in order to 
calculate the Health Dynamics data.  
Table 10: Health Dynamics (1-Strongly Disagree to 5-Strongly Agree) 
21. The medical information on diabetes management was accurate and timely? 
22. The recommendations or suggestions were consistent? 
23. The recommendations or suggestions made to you (or your patient) were relevant? 
24. The diabetes management plan will succeed or provide benefit? 
25. My outlook on diabetes improved? 
26. I trust the diabetes resources that were provided? 
27. The resources were readily available for the disease through the system? 
28. The dietary information was trustworthy? 
29. The dietary information was reasonable and do-able. 
30. I have (or your patient has) a better understanding of the food to eat to maintain my blood sugar. 
31. I trust the exercise information that was provided: 
32. The exercise information was relevant to your (or your patient 
33. I believe that I (or my patient) would follow the exercise guidelines closely. 
34. I believe that I (or my patient) will increase my exercise as a result of the information provided. 
35. The medical information was understandable and readable. 
36. The medical information was adequately explained. 
37. The medical information was complete and accurate. 
38. I intend to seek medical information from other sources online to validate information received on this site. 
39. I feel comfortable asking the Clinician (or Patient) for further explanation on (or understanding of) the medical 
information. 
40. The institution behind the telemedicine site had a high degree of ethics and morals. 
41. I felt a personal connection with the person with whom I was interacting online. 
42. With regards to this site, I trusted the flow of information. 
43. The interactions were timely and complete. 
44. I felt a great distance between myself and the person with whom I interacted. 
45. I prefer interacting in an online environment versus a live interaction. 
46. I trust the person on the other end of the conversation. 
47. I trust that private medical information would be managed appropriately and carefully to prevent unauthorized 
access by others? 
48. In the next six months, I will seek a personal visit with the Clinician rather than an online connection? 
49. I prefer to intersperse the live visits with online management. 
50. The Clinician (Patient) with whom you interacted had a high degree of ethics and morals. 
51. The Clinician (Patient) was dependable and reliable. 
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 Design elements were another key aspect focused upon in the research. In order to 
calculate the specific values, all survey questions that focused on user response to the 
design components of the system were included. Table 11 lists the survey questions that 
were included in this calculated variable. 
Table 11: Design Elements (1-Strongly Disagree to 5-Strongly Agree or multi-select) 
52. The page layout was easy to follow and understand. 
53. The page layout was consistent throughout the site? 
54. The site appeared to be professionally designed: 
55. The content of the site was easily accessed: 
56. The site content was visually appealing: 
57. The site was easy to navigate: 
58A. Colors 
58B. Design 
58C. Layout 
58D. Formatting 
58E. Font Size 
58F. Font Shape 
58G. Font Color 
59. Considering the design elements of the site, the site was consistent in its design and message? 
60. The medical content and visual content worked well together: 
61. Overall, the contents of the site support feelings of trust: 
62. The images and graphics contained on the site instill a sense of purpose and trust: 
63. The graphics and images were professional in appearance, design, and layout: 
64. The site should contain more graphic content: 
 
 The third category of independent variables is the calculated value of Outcomes Score. 
It is a subset of the Health Dynamics and only deals with the survey questions that were 
posed to users that directly related to the outcomes of the patient. Table 12 describes the 
survey questions that were included in this calculated category. 
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Table 12: Outcomes Score (1-Strongly Disagree to 5-Strongly Agree) 
21. The medical information on diabetes management was accurate and timely? 
22. The recommendations or suggestions were consistent? 
23. The recommendations or suggestions made to you (or your patient) were relevant? 
24. The diabetes management plan will succeed or provide benefit? 
25. My outlook on diabetes improved? 
26. I trust the diabetes resources that were provided? 
27. The resources were readily available for the disease through the system? 
28. The dietary information was trustworthy? 
29. The dietary information was reasonable and do-able. 
30. I have (or your patient has) a better understanding of the food to eat to maintain my blood sugar. 
31. I trust the exercise information that was provided: 
32. The exercise information was relevant to your (or your patient 
33. I believe that I (or my patient) would follow the exercise guidelines closely. 
34. I believe that I (or my patient) will increase my exercise as a result of the information provided. 
35. The medical information was understandable and readable. 
36. The medical information was adequately explained. 
37. The medical information was complete and accurate. 
38. I intend to seek medical information from other sources online to validate information received on this site. 
39. I feel comfortable asking the Clinician (or Patient) for further explanation on (or understanding of) the medical 
information. 
40. The institution behind the telemedicine site had a high degree of ethics and morals. 
 
 The last independent variable is Relationship Score and is calculated to determine the 
effect or relatedness of the interactions. This calculated value is comprised of the survey 
questions that impact this key variable. Table 13 illustrates the survey questions that were 
included in the calculated variable. 
 
Table 13: Relationship Score 
41. I felt a personal connection with the person with whom I was interacting online. 
42. With regards to this site, I trusted the flow of information. 
43. The interactions were timely and complete. 
44. I felt a great distance between myself and the person with whom I interacted. 
45. I prefer interacting in an online environment versus a live interaction. 
46. I trust the person on the other end of the conversation. 
47. I trust that private medical information would be managed appropriately and carefully to prevent unauthorized 
access by others? 
48. In the next six months, I will seek a personal visit with the Clinician rather than an online connection? 
49. I prefer to intersperse the live visits with online management. 
50. The Clinician (Patient) with whom you interacted had a high degree of ethics and morals. 
51. The Clinician (Patient) was dependable and reliable. 
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Internal Reliability of Scales 
 Utilizing Likert-like scales in research generally requires that some form of reliability 
metric is applied to determine the internal reliability of the combined scales (Shortliffe & 
Cimino, 2006; Hill & Lewicki, 2006). Therefore, a Cronbach’s Alpha test was performed 
to determine the reliability of the models, the results of which are demonstrated in Table 
14 (Shortliffe & Cimino; Hill & Lewicki). Cronbach’s Alpha is a measure of internal 
coefficient of reliability and supports the researcher in establishing that the data obtained 
is consistent. As detailed in Table 14, the values consistently were above 0.70, which is 
generally regarded as an acceptable limit (Shortliffe & Cimino; Hill & Lewicki). 
 
Table 14: Cronbach’s Alpha Reliability Results 
Group 
Question Set 
N of items 
Cronbach's 
Alpha 
C2C 
Trust Score 17 .834 
Health Dynamics 31 .847 
Design Elements 19 .824 
Relationship 11 .721 
Outcomes 20 .779 
Propensity to Trust 6 .858 
Attitude Towards Patient Clinician Interaction 8 .799 
C2P 
Trust Score 17 .857 
Health Dynamics 31 .851 
Design Elements 19 .891 
Relationship 11 .764 
Outcomes 20 .799 
Propensity to Trust 6 .721 
Attitude Towards Patient Clinician Interactions 8 .781 
P2C 
Trust Score 17 .848 
Health Dynamics 31 .847 
Design Elements 19 .876 
Relationship 11 .794 
Outcomes 20 .778 
Propensity to Trust 6 .755 
Attitude Towards Patient Clinician Interactions 8 .815 
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Simulator-Group Analysis 
 As the simulators were adjusted by the researcher to reflect the various trust attributes 
that had been identified, it was anticipated that the trust score would be reflective of the 
removal of those attributes.  Table 15 reflects the mean trust score for each category 
broken down by subgroup. As expected, the trust score reflects a linear reduction as the 
trust dynamics are removed.  
 
Table 15: Mean Trust Score for All Simulators 
Mean Trust_Score  
Main Group Subgroup Mean N Std. Deviation 
C2C A 3.7059 6 .11765 
B 3.0980 6 .29451 
C 2.6275 6 .38423 
Total 3.1438 18 .52854 
C2P A 3.7451 6 .20264 
B 3.1471 6 .27528 
C 2.7157 6 .39968 
Total 3.2026 18 .51960 
P2C A 3.9020 6 .20264 
B 3.4020 6 .21506 
C 2.8908 7 .30268 
Total 3.3715 19 .48865 
Total A 3.7843 18 .18927 
B 3.2157 18 .28319 
C 2.7523 19 .35919 
Total 3.2417 55 .51202 
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Hypothesis Testing 
Testing the six hypotheses was conducted through ANOVA tests for each category 
(Shortliffe & Cimino, 2006; Hill & Lewicki, 2006). The groups of participants were 
analyzed to determine the role of trust with regard to the Health Dynamics score, that is 
to determine how the Health Dynamics score as detailed in the independent variables 
section affects measures of trustworthiness of the telemedicine simulator. 
Perceived medical information is characterized as the Health Dynamics score, 
perceived relationship is characterized as the Relational score, perceived patient 
outcomes is characterized as the Disease State Management score, while design is coded 
as the Design Elements score. 
 
Hypothesis One 
Hypothesis One stated that the perceived content of medical information (i.e. lab 
results, kidney function, wound care, etc.) presented to the patient from the clinician will 
have a significant impact on the trustworthiness of the telemedicine application. The null 
hypothesis, based on a non-directional hypothesis, can be stated in the following way: 
There is no significant difference in the trustworthiness of the telemedicine 
application based on the degree of perceived content of medical information 
(Disease State Management variable) presented by the clinician to the patient. 
Table 16 illustrates the results of the ANOVA test on hypothesis one, which indicates the 
null hypothesis with a p<0.05 can be rejected. 
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Table 16: Hypothesis One ANOVA Test 
ANOVAa 
Trust_Score 
 Sum of Squares df Mean Square F Sig. 
Between Groups 2.696 1 2.696 28.615 .000 
Within Groups 1.602 17 .094   
Total 4.298 18    
a. Main Group = P2C 
 
 Hypothesis Two 
Hypothesis Two covers the same content as Hypothesis One, but from a different 
perspective, that of the clinician to the patient. Specifically, the perceived content of the 
medical information (i.e., diet, exercise, daily glucose logs) presented to the clinician 
from the patient will have a significant impact on the trustworthiness of the telemedicine 
application. The null hypothesis of this hypothesis can be stated as follows: 
There is no significant difference in the trustworthiness of the telemedicine 
application based on the degree of perceived content of medical information 
presented to the clinician from the patient. 
The results of the ANOVA test can be seen in Table 17, which indicates the null 
hypothesis with a p<0.05 can be rejected. 
 
Table 17: Hypothesis Two ANOVA Test 
ANOVAa 
Trust_Score 
 Sum of Squares Df Mean Square F Sig. 
Between Groups 2.564 2 1.282 9.493 .002 
Within Groups 2.026 15 .135   
Total 4.590 17    
a. Main Group = C2P 
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Hypothesis Three 
Hypothesis Three states the perceived content of the medical information (i.e., 
diagnosis, medical therapy, disease state management and treatment options) presented to 
the clinician from the clinician will have a significant impact on the trustworthiness of the 
telemedicine application. This can be stated as the null hypothesis in the following way: 
There is no significant difference in the trustworthiness of the telemedicine 
application based on the degree of perceived content of medical information 
presented to the clinician from the clinician. 
Table 18 illustrates the results of the ANOVA test for hypothesis three and indicates 
that the null hypothesis can be rejected with a p<0.05. 
 
Table 18: Hypothesis Three ANOVA Test 
ANOVAa 
Trust_Score 
 Sum of Squares df Mean Square F Sig. 
Between Groups 3.649 2 1.824 24.873 .000 
Within Groups 1.100 15 .073   
Total 4.749 17    
a. Main Group = C2C 
 
Hypothesis Four 
Hypothesis Four states the design elements (i.e., how the site is displayed or 
represented to the user) of the telemedicine system will have a significant impact on the 
perceived trustworthiness of the telemedicine application, measured across all stratified 
groups. The null hypothesis can be stated as: 
There is no significant difference in the trustworthiness of the telemedicine 
application, measured across all stratified groups, based on the design 
elements. 
102 
 
 
  
Table 19 represents the results of the ANOVA test associated with Hypothesis Four 
and indicates that the null hypothesis can be rejected with a p<0.05. 
 
Table 19: Hypothesis Four ANOVA Test 
ANOVA 
Trust_Score 
Main Group Sum of Squares Df Mean Square F Sig. 
C2C Between Groups 3.455 2 1.727 20.025 .000
Within Groups 1.294 15 .086   
Total 4.749 17    
C2P Between Groups 2.847 2 1.424 12.255 .001
Within Groups 1.743 15 .116   
Total 4.590 17    
P2C Between Groups 2.697 2 1.348 13.475 .000
Within Groups 1.601 16 .100   
Total 4.298 18    
 
Hypothesis Five 
Hypothesis Five states that the measure of perceived relationship between patient and 
clinician (bi-directional) will have a significant impact on the trustworthiness of the 
telemedicine application. This can be rewritten to produce a null hypothesis statement as 
follows: 
There is no significant difference in the trustworthiness of the telemedicine 
application based on the degree of perceived relationship between patient and 
clinician (bi-directional). 
 Table 20 illustrates the results of the ANOVA test on Hypothesis Five and 
demonstrates the null hypothesis with a p<0.05 can be rejected. 
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Table 20: Hypothesis Five ANOVA Test 
ANOVA 
Trust_Score 
Main Group Sum of Squares Df Mean Square F Sig. 
C2C Between Groups 3.885 2 1.943 33.739 .000
Within Groups .864 15 .058   
Total 4.749 17    
C2P Between Groups 3.445 2 1.722 22.558 .000
Within Groups 1.145 15 .076   
Total 4.590 17    
P2C Between Groups 2.504 2 1.252 11.168 .001
Within Groups 1.794 16 .112   
Total 4.298 18    
 
Hypothesis Six 
Hypothesis Six was stated as perceived patient outcome (bi-directional for patient and 
clinician) will have a significant impact on the trustworthiness of the telemedicine 
application. In this case, the null hypothesis can be stated as follows: 
There is no significant difference in the trustworthiness of the telemedicine 
application based on the degree of perceived patient outcome. 
 Table 21 illustrates that the null hypothesis for Hypothesis Six can be rejected with a 
p<0.05. 
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Table 21: Hypothesis Six ANOVA Test 
ANOVA 
Trust_Score 
Main Group Sum of Squares Df Mean Square F Sig. 
C2C Between Groups 3.649 2 1.824 24.873 .000
Within Groups 1.100 15 .073   
Total 4.749 17    
C2P Between Groups 2.564 2 1.282 9.493 .002
Within Groups 2.026 15 .135   
Total 4.590 17    
P2C Between Groups 2.696 1 2.696 28.615 .000
Within Groups 1.602 17 .094   
Total 4.298 18    
 
Research Questions 
 A number of questions were posed in Chapter 1 that was beyond the hypotheses of this 
research, which included the trust dynamics that may impede or support telemedicine. 
The researcher sees a number of factors that are specific in the success of telemedicine 
that are distinct from other factors. One of the primary factors involves the relationship 
between clinician and patient, which is quite distinct from other forms of commerce or 
exchange. It is often developed over time and is a delicate balance between the 
requirements of both the clinician and the patient. Trust also depends upon the risks 
associated with the participants; a patient presenting with a broken finger carries a 
distinct risk that may be less than a patient presenting with major trauma. Similar to other 
environments such as ecommerce or health portals (Slyke, Belanger, & Comunale, 2004; 
Sillence, Briggs, Fishwick, & Harris, 2004; Luo & Najdawi, 2004; Gefen, 2002), risk 
carries with it a great deal of consideration in the trust development life cycle. These 
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attributes are identified in the User-Centric portion of the trust model. The clinician and 
the patient each brings with them a certain set of standards, perceptions, needs, and 
factors that must be met in order for a sound and healthy relationship to be built. These 
factors are highly dynamic and dependent upon previous, current, and future physical 
states of the patient. If one party is not getting their needs met, the trust may be 
diminished. These aspects are quite unique from other forms of personal exchange that 
may occur. Certainly the fact that trust has been demonstrated to impact ecommerce 
(Gefen, 2002) translates into telemedicine, however, with telemedicine, there appears to 
be a deeper, diverse, and more robust formula that must be applied. 
 Health portals, ecommerce, and other tenets of human computer interaction have all 
demonstrated that trust is a key factor (Geffen, 2002; Sillence, Briggs, Fishwick, & 
Harris, 2004; Slyke, Belanger, & Comunale, 2004) with their own requirements and 
frameworks that have been developed. This research proposes a new approach to that of 
telemedicine, which accounts for numerous factors that are shown to create the 
telemedicine trust model. The framework that the researcher has examined in this model 
captures the unique and challenging aspects that are part of the dynamic interpersonal 
relationship that exists between clinician and patient.  
 One aspect that was discussed in Chapter 1 is the fact that telemedicine lags behind the 
development of other technology advances by 10-15 years (Goldschmidt, 2005). While 
considering the challenges that exist in understanding the nature of interpersonal 
relationships faced within the healthcare environment, this may not be such an anomaly. 
As the telemedicine trust model suggests, attention needs to be given not only to the 
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system but also the demands of the user. As the trust model matures within a system, it 
may be possible to increase the trust components, thus increasing adoption. 
 Chau and Hu (2004) describe telemedicine as a broad utilization of advanced 
telecommunications, networking, dissemination of expertise, distribution of information, 
and exchange of healthcare information or services between geographically disparate 
participants. However, the vast majority of services may be applied to underserved 
populations, which may require more focus on specific characteristics of the population. 
Underserved populations may pose unique challenges in regards to infrastructure, 
education, technologic aptitude, and compliance with medical recommendations. These 
all bring forth unique challenges that must be addressed. Future research should focus on 
these specific attributes to uncover some of the unique characteristics. 
Summary of Results 
 The goals of this research were to examine the role of trust within the telemedicine 
environment to establish the importance of trust dynamics. The research included the 
following stages: 
1. Survey of the telemedicine environment  
2. Construction of a set of core dynamics that represent the study areas 
3. Construction of a framework that establishes the Telemedicine Trust Model 
(TTM) 
4. Construction of a telemedicine simulator based upon the trust model 
5. Perform research including collecting survey data to test the six hypotheses; test 
the TTM via the respondents’ reactions to the simulator at when the levels of 
elements thought to produce trust were varied. 
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The survey of the telemedicine environment revealed that a gap exists between current 
adoption rates and the potential benefits of telemedicine. The environment is well suited 
to a framework that could potentially increase the adoption rates. Best practices in 
telemedicine certainly contribute to continued growth and adoption, but other elements 
also appear to have an influence. Increased exposure and attention to the trust dynamics 
could enhance the adoption rates and, over time, expand the user base of telemedicine. 
 The core models that were developed through the literature review represent key areas 
where trust could play a role. The SME reviews helped to establish the baseline for the 
analysis. Three iterations of the trust model were utilized to focus the model on the core 
attributes. The trust models represented in Figure 7, focused on two primary areas, user 
centric trust and system centric trust, and were tied together by online behavior. The 
model established that a system must be able to adapt to a wide range of users, both from 
a technical point of view and a medical point of view. The model compartmentalized the 
clinical dynamics, privacy elements, and design elements in order to identify the key 
areas of research.  
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Figure 7: Final Telemedicine Trust Model 
 
The SME feedback provided assistance in producing the final TTM model by building 
upon the initial model and enhancing the attributes that may influence trust. The survey 
results confirmed that the components of the trust model were intact and that the elements 
described in the system centric model hold. 
 The author utilized the TTM in the development of the simulators. The TTM was 
combined with best practices that were noted in the telemedicine environment survey, 
along with the development of a case study, diabetes management algorithms, and 
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evidence-based medical information. The researcher anticipated that the survey would 
reveal that trust would be based upon these dynamics.  
 The results of the hypothesis testing revealed that medical information from patient to 
clinician, clinician to patient, and clinician to clinician, design elements, relationship, and 
perceived outcomes of the patient would have a significant impact on the trust of the 
telemedicine system. All six null hypotheses were rejected, based upon the survey results 
and are outlined in Table 22. It was noted that as the trust dynamics were removed, the 
trust score followed a linear pattern of reduction, as expected. 
 
Table 22: Summary of Hypotheses 
Hypothesis  Null Hypothesis Statement Results of 
Significance 
Testing 
Comments 
H1 
Medical Information to 
patient from clinician has 
no impact on trust 
Rejected Medical Information to 
patient from clinician has a 
positive impact on trust 
H2 
Medical Information to 
clinician from patient has 
no impact on trust 
Rejected Medical Information to 
clinician from patient has a 
positive impact on trust 
H3 
Medical Information to 
clinician from clinician has 
no impact on trust 
Rejected Medical Information to 
clinician from clinician has a 
positive impact on trust 
H4  Design Elements have no impact on trust 
Rejected Design Elements have a 
positive impact on trust 
H5 
Measure of perceived 
relationship has no impact 
on trust 
Rejected Measure of perceived 
relationship has a positive 
impact on trust 
H6 
Perceived patient outcome 
has no impact on trust 
Rejected Perceived patient outcome 
has a positive impact on 
trust 
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Chapter 5 
Conclusions, Implications, Recommendations, and Summary 
 
Overview 
 Development of a framework for the successful design of telemedicine was examined 
through this research. The roles of various users, including clinicians and patients, were 
captured through the use of online simulators and online surveys. Medical information, 
design elements, disease state management, as well as privacy all proved to be positive 
attributes in the development of trust.  
Conclusions 
Trust is a highly dynamic, individualized, complex, and unique process that often 
depends upon numerous factors in its development. Developing a framework of trust 
cannot be placed in a simple algorithm as if it were a one-size-fits-all approach. This 
research demonstrated that trust factors that may be appropriate for one agent, may not be 
appropriate for another. In the field of telemedicine, numerous users must be able to 
realize trust from a user centric approach as well as a system centric approach. These 
factors are independent of one another and must be managed in a unique way. The 
framework that was developed from this research was based on the focused approach of 
the UCT and SCT aspects. 
User centric approaches must realize that trust depends upon the life experiences, 
personality traits, needs, and other factors that are specific to individuals or groups. In 
this sense, the research found that an individual’s propensity to trust played a role in the 
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development of trust. Beyond the user’s propensity to trust several other factors emerge 
as key attributes to the UCT model, these include knowledge based attributes, calculus 
based attributes, relational based attributes, as well as institutional attributes. 
Knowledge Based attributes were captured as part of the UCT due to the individual 
nature of these requirements. Clinicians would most often fit into this role for a 
telemedicine system, requiring a great deal of knowledge based information present in 
the system. However, patients may also play a significant role in this realm due to the fact 
that patients may choose to educate themselves on their disease, thus increasing the 
requirement for a more robust knowledge base. 
Calculus Based attributes represents the variability in how a user may form the 
foundation of trust in medicine, these could be areas that are outside of the other factors, 
yet are still important. This domain may be built upon numerous factors such as cultural 
norms, perceptions, exposure to the medical community, or other factors. 
Relational Based aspects include the formulation, expectation, need, or attributes 
associated with the ongoing clinician-patient relationship. This attribute plays a key role 
in the development of trust for some users. It would be important to recognize this as a 
UCT component due to the unique nature of relatedness. Some users may have a different 
interpretation of their own relationship needs and those of the user with which they are 
interacting. 
Institutional Based attributes are also unique in that they may supersede some other 
aspects, such as Knowledge Based, Calculus Based, or Relational Based attributes. This 
is most likely to occur in an environment that carries a very high profile, highly 
respected, and authoritative atmosphere. A user may feel that since they are interacting 
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with such a reputable institution, they may not need to be as concerned about other 
attributes. This is one attribute that may also feed back to the user’s propensity to trust 
due to the ongoing interactions or reputation. If the reputation of the institution is 
damaged along the way, it may alter the level of trust, thus shifting the model. 
Moving outside of the UCT environment the transition moves to the attribute for 
online behavior of the participant. It appears outside of the realm of both UCT and SCT 
due to its unique nature. It is somewhat of a hybrid of both UCT and SCT and certainly 
can be influenced by both, yet appears to carry enough uniqueness to remain separate.  
System Centric Trust is developed within the telemedicine application beginning with 
three primary categories. Within this area lies the most abundant resource for trust 
building within telemedicine design. The first category is the health related information 
that the user is exposed to, which must be accurate, timely and adaptable to the users 
needs. If the user is naïve to the disease, it may require more explanation and resources, 
while a well seasoned clinician may require a different set of resources.  
Privacy and security are also a primary focal point of SCT, and also a compliance 
issue with many regulatory agencies. Its importance must be recognized and the system 
must be able to demonstrate to the user the high importance that the system places on 
privacy and security, but it must also be manageable for the user. Some privacy and 
security features discovered by the researcher during attendance at conferences were 
found to be difficult and prone to user interface challenges. A delicate balance of 
usability and features will be required to support such a system. 
The final section of the SCT represents the design elements that are present. User 
design must meet the demands of the audience. In particular, they should be feature rich 
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with easy to follow structure and flow. Medical information can be difficult for some to 
comprehend, or users may present with disabilities such as visual, hearing, manual 
dexterity, or other concerns that limit their ability to interact with a telemedicine system. 
Another factor could be the vast amount of resources that may be available on a disease. 
This information must be managed so as not to overwhelm the user. Design will be a 
paramount component to the development of SCT, but it must not be viewed in isolation. 
Implications 
Theoretical Implications 
 Trust is a very complex and highly dynamic environment, wrought with challenges 
from an individual perspective, a system perspective, along with a component for 
reputation. The dynamic nature makes it especially challenging to capture any single 
group of attributes that are universally applicable. Many aspects are based on individual 
needs, preferences, and the propensity to trust. The framework developed from this study 
clearly illustrates that trust is based on a number of key factors, but carry different 
weights depending on the user.  
 From this research there appears to be an opportunity for much more in-depth analysis 
of the framework. The researcher sees a clear link between the framework developed and 
trust models developed for artificial neural networks. A logical step would be to examine 
the weights of each trust attribute, based on the user scenarios studied in this research, 
while training a database to improve the overall trust score for each user.   
Telemedicine Implications 
 Telemedicine has experienced numerous hurdles with regards to adoption of the 
technology. Establishing a stronger foundation of trust with all involved may help to 
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foster a greater adoption rate. This research has demonstrated that there exist areas for 
improvement and further exploration. Trust attributes should be considered by both 
telemedicine developers and implementers.  
The field of medicine is constantly evolving with increased scrutiny with regards to 
privacy, HIPAA regulations, security, patient safety and outcomes, appropriate use 
criteria, evidence-based medicine, personalized medicine, and vast arrays of 
developments in all fields. This exponential expansion of medicine creates an ideal 
environment for technology to help manage and foster. However, systems have to 
consider all aspects of users in order to become fully effective. What the user brings to 
the table in terms of their predisposition is only a small portion of the user perspective.  
In terms of clinicians, there needs to be a strong and consistent effort to develop robust 
and engaging environments that capture the diversity that exists in medical care. The 
practice of medicine creates a challenge due to the variety of approaches and thought 
processes that clinicians employ. Certainly best practices, evidence based medicine, 
treatment algorithms, standards of care, and disease state management techniques help to 
support levels of trust, but attention needs to be paid to more than just those items.  
On the side of the patient, attention needs to be placed on not only patient outcomes 
but also on supporting the patient from their perspective. Some patients will be highly 
informed and educated on their disease, while others will have little knowledge or interest 
in learning much about their disease. Technology needs to assist all patient types, not just 
limit itself to a narrow spectrum of the patient group. 
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Recommendations 
 Telemedicine has vast opportunities to improve usability and increase trust with the 
various agents that will be interacting with the system. Trust can play a role in developing 
and supporting those systems. The trust framework developed from this research can help 
to guide development of more robust studies within this area. 
 The researcher also sees a unique opportunity to expand the trust model into an 
artificial neural network environment by labeling the trust attributes with user specific 
weights. Measuring the fluctuation in the weight of the trust attribute and capturing the 
data in a database table, the system could theoretically change the nature of the 
presentation to gain the maximum level of trust for the user. This approach is modeled in 
Figure 8. 
 Considering that a robust telemedicine system would have numerous opportunities to 
increase trust as the dynamic nature of disease state management unfolds, perhaps an 
artificial neural network (ANN) would prove beneficial. Medicine and disease state 
management are a constantly evolving paradigm, something that may be appropriated 
from other trust based systems such as e-commerce.  
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Figure 8: Suggested Future Research ANN Model 
Summary 
 This study focused on the development of a framework that would enhance the level 
of trust in a telemedicine system. The framework developed illustrates the complex 
nature of trust in telemedicine and the challenges faced by developers to enhance overall 
adoption rates and trust within a system.  
 Chapter 1 focused on the description of the environment of telemedicine and the 
need for the study. The problem that the researcher introduced laid the foundation for the 
research. The focus was on the significant divergence in the adoption and adaptation of 
technology within the healthcare and medical community. It was suspected that this 
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divergence, which may be rooted in a lack of trust in the technology being applied, may 
hinder the advancement and treatment of patients, thus increasing morbidity and 
mortality. The barriers of the research were also introduced and ways the researcher 
would attempt to minimize their impact were discussed.  
 Chapter 2 contained a rich examination of the literature, exploring the research of 
medicine, telemedicine, diabetes, trust, and the various aspects studied. Much of the 
literature review focused on trust dynamics and how they have evolved over time. 
Telemedicine has also faced the challenge of improving adoption rates; this creates a 
strong incentive for the examination of trust in telemedicine to determine if any 
correlations exist between adoption rates and trust.  
 This research focused on three specific user groups and how trust could impact each 
group. This was outlined in Chapter 3, the methodology section. A simulator was 
developed that explored the dynamics of trust with regards to the treatment of diabetes 
mellitus, a common disease. Participants were grouped as a clinician based on their 
background, if they had clinical training or a graduate degree in life science. Other 
participants acted as patients being treated by the clinician. Following the simulated 
exercise, the participants were asked to take a survey. 
 Chapter 4 outlines the results of the simulated environment and the survey, where the 
data indicated that the trust dynamics of relationship, clinical data, outcomes, and system 
design were all significantly tied to trust of the telemedicine system. The researcher has 
also offered insight into what areas may require more research to understand the 
dynamics of trust and telemedicine.  
118 
 
 
  
 This research has shed light into the complex and dynamic world of telemedicine and 
some of the factors that may influence the low adoption rates. Adoption, as pointed out in 
the literature review, has been significantly delayed when compared to other technology 
sectors. This research has been carried out to potentially influence and alter the landscape 
in terms of telemedicine. Certainly more research should be done to continue to discover 
the attributes that influence the ways in which medicine can be practiced. For diseases 
such as diabetes, the more opportunities for education and disease state management, the 
more opportunities there will be to slow the devastating progression of this and other 
diseases. Telemedicine has abundant opportunities to have a positive impact on the health 
of future generations, but understanding the fundamental ways in which to deliver that 
healthcare is paramount.  
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Appendix A 
 
Letter to Research Participants (Patients and Clinicians) 
 
 
James R. Templeton 
7770 Regents Road 
#113-602 
San Diego, CA 92122 
jtemplet@nova.edu 
 
January 2, 2010 
 
 
Dear Participant, 
 
My name is James Templeton and I am a graduate student at Nova Southeastern 
University conducting research on the elements of trust in telemedicine. The focus of the 
research will be on how well diabetic patients and clinicians manage their disease to 
improve outcomes in order to build a framework for the successful design of 
telemedicine systems. I am developing a survey questionnaire that will help to define the 
specific attributes that enhance trust in these systems. I am hoping that you will join me 
in this exciting and important research study. 
 
The study will be conducted during a twelve-week period between January 5, 2010 and 
March 20, 2010. For each participant, the entire study should take about 30 minutes to 
complete. NSU’s Institutional Review Board (IRB) has approved this research. Please 
note that at no time will any personally identifiable data be collected on any participant.  
 
If you are interested in participating in this research study, additional information can be 
found at www.trusttelemedicine.com. Please feel free to visit the web site for a more 
detailed explanation of the study design and research.  
 
In addition, participants in the study will each receive a $5 gift card. Three participants 
will also be randomly selected to receive a $75 gift card. This will be managed by a third 
party website ensuring the anonymity of the user throughout the process. 
 
Thank you very much for your support and participation in this research. Your 
participation is very important to me and to the advancement of the body of knowledge in 
this area. 
 
 
Sincerely, 
 
James R. Templeton  
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Appendix B 
Letter to Diabetes Subject Matter Experts 
James R. Templeton 
7770 Regents Road, #113-602 
San Diego, CA 92122 
jtemplet@nova.edu 
 
November 1, 2009 
Dear Colleague, 
 
My name is James Templeton and I am a graduate student at Nova Southeastern 
University conducting research on the elements of trust in telemedicine. The focus of the 
research will be on how well diabetic patients and clinicians manage their disease to 
improve outcomes in order to build a framework for the successful design of 
telemedicine systems. I am developing a survey questionnaire that will help to define the 
specific attributes that enhance trust in these systems. Specifically, I am hoping that you 
will assist me in determining the most important parameters of diabetes care by ranking 
the importance of the following categories: 
 
_____ Patient Education (patient comprehension for diabetes management) 
_____ Patient Compliance 
_____ Fasting Glucose Levels 
_____ Postprandial Glucose Levels 
_____ HbA1C testing 
_____ Diet/Weight Management 
_____ Exercise 
_____ Wound Care 
_____ Cardiovascular Disease - Cholesterol 
_____ Cardiovascular Disease - Hypertension 
_____ Diabetic complications (i.e. Nephropathy and Neuropathy) 
_____ Family History, Demographics, and Race 
 
Please rank the above with the number 1 applied to the most important category. Also, 
feel free to rank ties accordingly (i.e. two items can rank first, if desired). Feel free to 
comment briefly on the reverse side to provide further insight into the management of 
diabetes. 
 
Additional information can be found at www.trusttelemedicine.com. Please visit the web 
site at any time for a more detailed explanation of the study design and research. You 
may also visit in the future to review the outcomes of the study. 
 
Please return the information within two weeks via the postage paid envelope. Thank you 
very much for your support and participation in this research.  
 
Sincerely, 
James R. Templeton  
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Appendix C 
 
Letter to Trust Subject Matter Experts – Trust Dynamics 
 
James R. Templeton 
7770 Regents Road 
#113-602 
San Diego, CA 92122 
jtemplet@nova.edu 
 
November 1, 2009 
 
Dear Colleague, 
 
My name is James Templeton and I am a graduate student at Nova Southeastern 
University conducting research on the elements of trust in telemedicine. This research 
focuses on diabetic patients and clinicians managing diabetes in order to improve 
outcomes. The goal of the research is to build a framework for the successful design of 
telemedicine systems. I am developing a survey questionnaire that will help to define the 
specific attributes that enhance trust in these systems. Specifically, I am hoping that you 
will assist me in determining the most important parameters of diabetes care by 
answering the following questions (please use the reverse side if additional space is 
needed): 
 
Did you find bias (preference towards any issue or idea) in the trust dynamics identified? 
________________________________________________________________________ 
If yes, what recommendations would you have to eliminate or minimize these biases? 
________________________________________________________________________ 
Did you find the trust dynamics to be a reliable approach? 
________________________________________________________________________ 
Would any trust dynamics benefit from rewording, rephrasing, or replacement? 
________________________________________________________________________ 
What is missing from the trust dynamics? 
________________________________________________________________________ 
What would you do to improve the trust dynamics identified? 
________________________________________________________________________ 
 
Additional information can be found at www.trusttelemedicine.com. Please feel free to 
visit the web site at any time for a more detailed explanation of the study design and 
research.  
 
Thank you very much for your support and participation in this research.  
 
Sincerely, 
 
James R. Templeton  
122 
 
 
  
Appendix D 
 
Letter to Trust Subject Matter Experts – Participants Survey 
 
James R. Templeton 
7770 Regents Road 
#113-602 
San Diego, CA 92122 
jtemplet@nova.edu 
 
November 1, 2009 
 
Dear Colleague, 
 
My name is James Templeton and I am a graduate student at Nova Southeastern 
University conducting research on the elements of trust in telemedicine. This research 
focuses on diabetic patients and clinicians managing diabetes in order to improve 
outcomes. The goal of the research is to build a framework for the successful design of 
telemedicine systems. I am developing a survey questionnaire that will help to define the 
specific attributes that enhance trust in these systems. Specifically, I am hoping that you 
will assist me in determining the most important parameters of diabetes care by 
answering the following questions (please use the reverse side if additional space is 
needed): 
 
Did you find any bias (preference towards any issue or idea) in the survey? 
________________________________________________________________________ 
If yes, what recommendations would you have to eliminate or minimize these biases? 
________________________________________________________________________ 
Did you find the survey questions readable and understandable to a layperson? 
________________________________________________________________________ 
Would any survey questions benefit from rewording or rephrasing? 
________________________________________________________________________ 
What is missing from the survey? 
________________________________________________________________________ 
What would you do to improve the survey? 
________________________________________________________________________ 
 
Additional information can be found at www.trusttelemedicine.com. Please feel free to 
visit the web site at any time for a more detailed explanation of the study design and 
research.  
 
Thank you very much for your support and participation in this research.  
 
Sincerely, 
 
James R. Templeton  
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Appendix E 
 
Trust Dynamics 
 
Trust dynamics are described as a spectrum within which most people operate in their 
interactions with the environment and specific situations.  
 
 
 
 
Baseline trust dynamics are established via a propensity to trust scale. The following 
questions are posed to develop the baseline values of trust from the perspective of a 
subject. 
 
Trust Propensity (general attitude)– 
 
1. Do you consider yourself a trusting person? 
 
o Yes 
o No 
o Sometimes 
 
2. Do you trust until proven otherwise? 
 
o Yes 
o No 
o Sometimes 
 
3. Do you consider yourself to have trust issues? 
 
o Yes 
o No 
o Sometimes 
 
4. Do you generally believe in others? 
 
o Yes 
o No 
o Sometimes 
 
5. In general, do you have trust when you are using the Internet? 
 
o Yes 
o No 
o Sometimes 
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6. Do you have trust in online medical information? 
 
o Yes 
o No 
o Sometimes 
 
 
Another baseline trust dynamic will be established via the patient/clinician interaction 
scale. This category reflects how patients and clinicians view their interactions, how they 
view perceptions of medical, health, privacy, and other online aspects. This psychometric 
scale is determined by the following questions: 
 
Patient and/or Clinician Interactions – 
 
7. How often do you visit a doctor? 
 
o Only when needed 
o Monthly 
o Quarterly (every three months) 
o Twice/Year 
o Once/Year 
o Less than Once/Year 
o Never 
 
8. How would you rate your general health? 
 
o Excellent 
o Good 
o Fair 
o Poor 
o Don’t know 
 
9. In the last 6 months, how often have you sought medical 
information online? 
 
o Never 
o 1 - 2 
o 3 - 5 
o 6 - 10 
o More than 10 
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10. How would you rate your medical search experience? 
 
o Excellent 
o Very Good 
o Good 
o Fair 
o Poor 
o I don’t know how to do medical searches online 
 
11. How would you rate the quality of medical information online? 
 
o Excellent (never had any complaints or problems) 
o Very Good (minimal complaints or problems) 
o Good (some complaints or problems) 
o Fair (frequent complaints or problems) 
o Poor (numerous complaints or problems) 
o N/A (I do not search medical information online) 
 
12. Do you have any future intention of conducting online medical 
search? 
 
o Definitely plan to conduct online search for medical 
data 
o Probably will conduct online search for medical data 
o Might conduct online search for medical data 
o Probably will NOT conduct online search for medical 
data 
o Most definitely will NOT conduct online search for 
medical data 
 
13. In general, are you concerned about your personal privacy (or 
patient privacy) of medical information online? 
 
o Yes 
o No 
o Don’t Know (never really considered it) 
 
14. In communicating medical information online, are you 
concerned that the communication may not be received or 
communicated correctly? 
 
o Yes 
o No 
o Don’t Know (never really considered it) 
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The specific trust dynamics that are associated with the simulators are broken down into 
two primary categories, Health Dynamics and Design Elements.  
 
 
Health Dynamics  
 - Diabetes Management                   
 - Diabetes Resources                    
 - Dietary Information                    
 - Exercise Information                    
 - Medical Information                    
 - Patient and/or Clinician Interactions               
 
Design Elements 
 - Page Layout                       
 - Navigation                       
 - Graphics Layout          
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Appendix F 
 
Research Survey Model 
 
 
 
Category                       Questions 
 
Demographics                       1-5 
 
Trust Propensity                      6-11 
 
Patient and/or Clinician Interactions               12-15 
 
Health Dynamics  
 - Diabetes Management                  20-24 
 - Diabetes Resources                   25-26 
 - Dietary Information                   27-29 
 - Exercise Information                   30-33 
 - Medical Information                   34-39 
 - Patient and/or Clinician Interactions              40-50 
 
Design Elements 
 - Page Layout                      51-55 
 - Navigation                      56-60 
 - Graphics Layout                    61-63 
 
General Overview                     64-70 
 
 
The survey which will be utilized in the research is provided in Appendix E. The online 
version will contain the following modifications: 
 
1. Survey questions will be specific to the choice made in question 1 (Patient or 
Clinician) 
2. Headings will be removed and categorized by Roman Numerals 
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Appendix G 
Survey Questions 
 
Computer/Technology Savvy –  
 
1. How would you rank your computer/online literacy (select 
one)? 
         
o Computer/Online Expert 
o Computer/Online Proficient 
o Computer/Online Sufficient 
o Computer/Online Novice 
 
Topic Categories - 
 
 Demographic Information – 
 
2. What Communication Category did you participate in (select 
one)? 
 
o Patient to Clinician 
o Clinician to Patient 
o Clinician to Clinician 
 
3. What is your age (Select one)? 
 
o 18 – 25 
o 26 – 35 
o 36- 45 
o 46-55 
o 56-65 
o >65 
 
4. Gender (Select one)? 
 
o Male 
o Female 
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5. Household Income Annually (Optional): 
 
o < 25,000  
o 25,000 –49,999 
o 50,000 – 74,999 
o 75,000 – 99,999 
o 100,000 – 124,999 
o 125,000 – 149,999 
o 150,000 – 199,999 
o 200,000 +  
 
6. Education: 
 
o Not High School Graduate 
o High School Graduate 
o Some College 
o Associates Degree/Trade School 
o Bachelors Degree/Advanced Trade School 
o Masters Degree 
o MBA 
o Non-Clinical Professional (Lawyer, Architect, etc.) 
o Clinical Professional (Physician, or Health Care 
Professional, i.e. Nurse, Certified Diabetic 
Educator, PharmD, etc.) 
o Doctorate – Life Sciences (PhD, PsyD, DSc, etc.) 
o Doctorate – Non Life Sciences (EdD, PhD, etc.) 
 
Trust Propensity (general attitude)– 
 
7. Do you consider yourself a trusting person? 
 
o Yes 
o No 
o Sometimes 
 
8. Do you trust until proven otherwise? 
 
o Yes 
o No 
o Sometimes 
 
9. Do you consider yourself to have trust issues? 
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o Yes 
o No 
o Sometimes 
 
 
 
10. Do you generally believe in others? 
 
o Yes 
o No 
o Sometimes 
 
11. In general, do you have trust when you are using the Internet? 
 
o Yes 
o No 
o Sometimes 
 
12. Do you have trust in online medical information? 
 
o Yes 
o No 
o Sometimes 
 
 Patient and/or Clinician Interactions – 
 
13. How often do you visit a doctor? 
 
o Only when needed 
o Monthly 
o Quarterly (every three months) 
o Twice/Year 
o Once/Year 
o Less than Once/Year 
o Never 
 
14. How would you rate your general health? 
 
o Excellent 
o Good 
o Fair 
o Poor 
o Don’t know 
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15. In the last 6 months, how often have you sought medical 
information online? 
 
o Never 
o 1 - 2 
o 3 - 5 
o 6 - 10 
o More than 10 
 
16. How would you rate your online medical search experience? 
 
o Excellent 
o Very Good 
o Good 
o Fair 
o Poor 
o I don’t know how to do medical searches online 
 
17. How would you rate the quality of medical information online? 
 
o Excellent (never had any complaints or problems) 
o Very Good (minimal complaints or problems) 
o Good (some complaints or problems) 
o Fair (frequent complaints or problems) 
o Poor (numerous complaints or problems) 
o N/A (I do not search medical information online) 
 
18. Do you have any future intentions of conducting online 
medical searches? 
 
o Definitely plan to conduct online search for medical 
data 
o Probably will conduct online search for medical data 
o Might conduct online search for medical data 
o Probably will NOT conduct online search for medical 
data 
o Most definitely will NOT conduct online search for 
medical data 
 
19. In general, are you concerned about your personal privacy (or 
patient privacy) of medical information online? 
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o Yes 
o No 
o Don’t Know (never really considered it) 
 
20. In communicating medical information online, are you 
concerned that the communication may not be received or 
communicated correctly? 
 
o Yes 
o No 
o Don’t Know (never really considered it) 
  
 
Health Dynamics – 
 
   Diabetes Management - 
 
21. Do you trust that the medical information on diabetes 
management was accurate and timely? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
22. Did you feel that the recommendations or suggestions were 
consistent? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
23. Did you feel the recommendations or suggestions made to you 
(or your patient) were relevant? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
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24. Do you believe the diabetes management plan will succeed or 
provide benefit? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
25. Has your outlook on diabetes has improved? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
    Diabetes Resources – 
 
26. Did you trust the diabetes resources that were provided? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
27. Did you feel that the resources were readily available for the 
disease through the system? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
    Dietary Information – 
 
28. Do you feel the dietary information was trustworthy? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
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29. Do you feel the dietary information was reasonable and 
doable? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
30. Do you (or does your patient) have a better understanding of 
the food you need to eat to maintain your blood sugar? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
   Exercise Information – 
 
31. Did you trust the exercise information that was provided? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
32. Was the exercise information relevant to your (or your 
patient’s) lifestyle and ability? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
33. Do you believe that you (or your patient) would follow the 
exercise guidelines closely? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
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34. Do you believe that you (or your patient) will increase your 
exercise as a result of the information provided? 
 
o No 
o Some Increase 
o Neutral 
o Moderate Increase 
o Absolutely, I have adopted a regular exercise routine 
 
 
 
   Medical Information – 
 
35. Did you feel the medical information was understandable and 
readable? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
36. Did you feel the medical information was adequately 
explained? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
37. Do you trust that the medical information was complete and 
accurate? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
38. Do you intend to seek medical information from other sources 
online to validate information? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
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o Agree 
o Strongly Agree 
 
39. Would you feel comfortable asking the Clinician (Patient) for 
further explanation on the medical information? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
  
40. Do you believe the institution behind the telemedicine site had 
a high degree of ethics and morals? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
Patient and/or Clinician Interactions  
 
41. Did you feel a personal connection with the person with whom 
you were interacting online? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
42. Did you trust the flow of information? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
43. Did you believe that interactions were timely and complete? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
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o Agree 
o Strongly Agree 
 
44. Did you feel a great distance between yourself and the person 
with whom you interacted? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
45. Do you prefer interacting in an online environment versus a 
live interaction? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
46. Did you trust the person on the other end of the conversation? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
47. Did you trust that private medical information would be 
managed appropriately and carefully to prevent unauthorized 
access by others? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
48. In the next six months, will you seek a personal visit with the 
Clinician (or Patient) rather than an online connection? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
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o Strongly Agree 
 
49. Do you prefer to intersperse the live visits with online 
management? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
50. Do you believe that the Clinician (Patient) with whom you 
interacted had a high degree of ethics and morals? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
51. Do you believe that the Clinician (Patient) was dependable and 
reliable? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
  
  Design Elements - 
 
   Page Layout – 
 
52. Did you feel the page layout was easy to follow and 
understand? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
53. Did you feel the page layout was consistent throughout the 
site? 
 
o Strongly Disagree 
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o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
54. Do you feel the site appeared to be professionally designed? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
 
55. Do you feel that the content of the site was easily accessed? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
56. Do you feel that the site content was visually appealing? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
   Navigation – 
 
57. Do you feel that the site was easy to navigate? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
58. Considering the design elements of the site, do you consider 
the following aspects to have been visually appealing (choose 
all that apply)? 
 
o Colors 
o Design  
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o Web Layout 
o Formatting 
o Font Size 
o Font Shape 
o Font Color 
 
59. Considering the design elements of the site, do you feel that the 
site was consistent in its design and message? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
 
60. Do you believe that the medical content and visual content 
work well together? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
61. Overall, do you feel that the contents of the site support 
feelings of trust? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
   Graphics Layout – 
 
62. Do you feel that the images and graphics contained on the site 
instill a sense of purpose and trust? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
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63. Do you believe that the graphics and images were professional 
in appearance and design and layout? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
64.  Would you recommend more graphic content on the site? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
 
  General Overview – 
 
65. Do you feel that the privacy policy influenced your feelings of 
the site? 
 
o Strongly Disagree 
o Disagree 
o Neutral 
o Agree 
o Strongly Agree 
o I did not read the privacy policy 
 
66.  Of the following, do you consider any single aspect of the site 
the most important feature (select one, if appropriate): 
 
o Medical Content 
o Access to Clinician (Patient) 
o Disease State Management 
o Navigation of Site 
o Availability 
o Privacy Policy 
 
67. Of the following medical components, which do you feel stand 
out as a key point in your level of trust in the system (Choose 
all that apply)? 
 
o Diabetes Management 
o Dietary Management 
o Exercise Management 
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o Clinician comments/suggestions 
 
68. Of the following design elements, which would you consider to 
stand out as key points in your level of trust in the system 
(choose all that apply)? 
 
o Navigation of Website 
o Color Scheme 
o Font Size 
o Graphics and Images 
o Page Layout 
 
69. Do any of the following security and privacy features stand out 
as a key point in your level of trust in the system (choose all 
that apply)? 
 
o Secure Site 
o Privacy Policy 
o HIPPA Policy 
o Private communication with Clinician (Patient) 
 
70. How would you estimate your level of trust with telemedicine 
based on your experience with this site? 
 
o No Trust 
o Some Trust 
o Trust 
o Moderate Trust 
o Complete Trust 
 
71. Would you be willing to recommend telemedicine to others 
through your experience with this site? 
 
o Strongly Agree 
o Agree 
o Neutral 
o Disagree 
o Strongly Disagree 
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Appendix H 
 
 
Sample Size - Statistical Design and Analysis 
 
Definition of terms: 
 
n= Sample number 
x  = Sample mean 
s2 = Sample variance 
s = Sample standard deviation 
µ = Population mean 
H0 = Null hypothesis 
Ha = Alternative hypothesis 
H1 = Hypothesis 
 = Population standard deviation 
2 = Population variance 
 
Hypotheses: 
H1 = Trust dynamics have a bearing on the adoption of telemedicine 
H0 = Trust dynamics do not have a bearing on the adoption of telemedicine 
 
Objective: 
Hypothesis testing to either accept or reject the null hypothesis H0 
Determine, through Statistical Inference, the impact of trust dynamics on the treatment 
of diabetes through a telemedicine system 
 
Population:  
 Prevalence of Diabetes; Global = 300,000,000 people 
 Prevalence of Diabetes; US = 20,000,000 people 
  
Sample Size and Calculation: 
  
N = Sample Size 
 Sample pool = Random 
 Sample Parameters:  
 
A) Patient - Person with Type I Diabetes  
B) Patient - Person with Type II Diabetes  
C) Patient - Person with Impaired Glucose Tolerance 
D) Patient - Person with Pre-Diabetes 
E) Clinician - MD, DO, PharmD, CDE, NP, PA, RN, PhD, RD 
 
Potential Systematic Bias: potential bias exists in the sample due to access to and 
understanding of technology. Lower income or elderly diabetic patients may not 
144 
 
 
  
have access to the Internet, may not own a computer, or understand how to utilize 
a system such as simulated medical environment. This results in a potential bias in 
the sample pool by eliminating their potential to participate (Hill & Lewicki, 
2006).  
 
Random Sample Error: Potential to overestimate the results due to bias that exists 
in the selected sample pool. Participants may offset the results through the 
clustering of the samples (Hill & Lewicki, 2006). 
 
Central Limit Theorem = States that a sample size will be fairly normal (i.e. 
follow a normal curve) for large sample sizes (N>30) (Hill & Lewicki, 2006).  
 
According to the Central Limit Theorem, the mean of a sampling distribution of 
means is an unbiased estimator of the population mean. 
    
µ x = µ 
 
Similarly, the standard deviation of a sampling distribution of means is  
    
x = 
n

 
 
The larger the sample, the less the variation of the sample mean. This value is also 
known as the standard error of the mean. Every statistic has a standard error, 
which is the measure of a statistics random variability. 
 
Considering that the sample n > 30, the Central Limit Theorem allows for 
consideration of the properties of a normal curve. The normal curve indicates that 
95% of all values relevant to the mean will be found within  2 , or with two 
standard deviations of the mean (Hill & Lewicki, 2006). 
 
Additionally, the area of the normal curve must be standardized by converting it 
to a z-score. To convert a value to a z-score is to express it in terms of how many 
standard deviations it is above or below the mean.  
 
 
   z = 
x  
 
Where x is the value to be converted, µ is the population mean, and σ is the 
population standard deviation. 
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Sample Size Calculation 
 
 
Sample size calculation requires a careful balance of resources, needs, and 
requirements. To obtain a smaller, more precise margin of error of the 
population’s proportion, we must either decrease the degree of confidence or 
increase the sample size. Similarly, if we want to increase the degree of 
confidence, we may either accept a wider margin of error or increase the sample 
size.  
 
In setting up a survey to obtain a confidence interval estimate of the population 
proportion, what should we use for σ p ?  Using the formula n
)1(   we find 
that the largest value that it can be is
n
5.0 .  This will be the basis for the 
determination of the sample size for this study. 
 
Another factor to consider is the Confidence Level, which will be considered at 
85%, 90%, 95%, or 99%. In order to utilize these values, the z-score must be 
obtained for each. They are as follows:  
 
 
Table 23: Confidence Level 
 
Confidence 
Level
z-
score 
85% 1.04 
90% 1.28 
95% 1.96 
99% 2.32 
 
The last factor to consider is the Margin of Error, which represents a certain 
percentage above or below the amount obtained when applied to the population of 
the group (Hill & Lewicki, 2006). The Margin of Error is inversely related to 
sample size, to a point; it is also directly related to the confidence level. In other 
words, as sample sizes increase, the margin of error begins to decrease. However, 
as sample sizes get larger, the rate of change for the margin of error slows down 
and becomes very difficult to eliminate. Furthermore, a decrease in the confidence 
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level makes it easier to tighten the Margin of Error. All of these factors are related 
in the following formula: 
 
E
n
CL )5.0(  where CL represents the Confidence Level converted to a z-score 
and E represents the Margin of Error  
 
Based on the above calculations, the following tables represent the varying 
margin of errors and confidence levels at a variety of sample sizes.  
 
 
 
Table 24: Minimal Margin of Error Calculations to Determine Sample Size 
Confidence 
Level z-score 
Margin of 
Error Constant
 
 
Sample 
size 
      
85% 1.04 0.025 0.5 20.8 433
 1.04 0.05 0.5 10.4 108
 1.04 0.075 0.5 6.933333 48
 1.04 0.1 0.5 5.2 27
 1.04 0.125 0.5 4.16 17
90% 1.28 0.025 0.5 25.6 655
 1.28 0.05 0.5 12.8 164
 1.28 0.075 0.5 8.533333 73
 1.28 0.1 0.5 6.4 41
 1.28 0.125 0.5 5.12 26
95% 1.96 0.025 0.5 39.2 1537
 1.96 0.05 0.5 19.6 384
 1.96 0.075 0.5 13.06667 171
 1.96 0.1 0.5 9.8 96
 1.96 0.125 0.5 7.84 61
99% 2.33 0.025 0.5 46.6 2172
 2.33 0.05 0.5 23.3 543
 2.33 0.075 0.5 15.53333 241
 2.33 0.1 0.5 11.65 136
 2.33 0.125 0.5 9.32 87
 
 
n
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Table 25: Realistic Sample Size Comparison to Determine Margin of Error 
 
 
 
 
 
Sample Size Comparison to Determine Margin of Error 
 
In order to establish an appropriate sample size that is within time, budgetary, and 
resource constraints, either the Confidence Level or the Margin of Error must be 
adjusted (Hill & Lewicki, 2006). In this case, the researcher has determined that a 
95% Confidence Level is an appropriate level for the study. Therefore, the 
researcher must accept a high Margin of Error in order to accommodate the 
relatively high Confidence Level and lower N. 
 
As highlighted above, the researcher has selected a 95% Confidence Level, a 
13.3% Margin of Error, and a Sample Size of 54.  
 
Confidence 
Level z-score 
Margin of 
Error Constant
 
 
n-
squared 
      
85% 1.04 0.134263423 0.5 3.872983 15
 1.04 0.122565175 0.5 4.242641 18
 1.04 0.104 0.5 5 25
 1.04 0.094938577 0.5 5.477226 30
 1.04 0.070763037 0.5 7.348469 54
90% 1.28 0.165247289 0.5 3.872983 15
 1.28 0.150849447 0.5 4.242641 18
 1.28 0.128 0.5 5 25
 1.28 0.116847479 0.5 5.477226 30
 1.28 0.087092969 0.5 7.348469 54
95% 1.96 0.253034912 0.5 3.872983 15
 1.96 0.230988215 0.5 4.242641 18
 1.96 0.196 0.5 5 25
 1.96 0.178922702 0.5 5.477226 30
 1.96 0.133361108 0.5 7.348469 54
99% 2.33 0.300801707 0.5 3.872983 15
 2.33 0.274593133 0.5 4.242641 18
 2.33 0.233 0.5 5 25
 2.33 0.212698926 0.5 5.477226 30
 2.33 0.158536419 0.5 7.348469 54
n
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Appendix J 
AACE/ACE Diabetes Algorithm for Glycemic Control 
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Appendix K  
Evidence Based Medicine Model 
Reasoning/Justification of treatment: 
The following table represents an examination of randomized controlled trials (RCTs) 
with combination therapy in naïve patients:  
Randomized Controlled Trial -  
Drug Combination Therapy in Naïve 
Patients 
Total HbA1C Decreases (%)a 
Rosiglitazone + metformin 
(N = 468, 32 weeks)[15] 
Rosiglitazone 8 mg + metformin 2000 mgd 2.3b 
Rosiglitazone 8 mgd 1.6 
Metformin 2000 mgd 1.8 
Rosiglitazone + glimepiride 
(N = 901, 28 weeks) [9] 
Rosiglitazone 8 mg + glimepiride 4 mg 2.5b 
Rosiglitazone 8 mg 1.8 
Glimepiride 4 mg 1.7 
Saxagliptin + metformin 
(N = 1306, 24 weeks)[12] 
Saxagliptin 10 mg + metformin 2.5b 
Saxagliptin 10 mg 1.7 
Metformin 2000 mg 2.0 
Vildagliptin + metformin  
(N = 1179, 24 weeks)[8] 
Vildagliptin 100 mg + metformin 2000 mg 1.8b 
Vildagliptin 100 mg 1.1 
Metformin 2000 mg 1.4 
Sitagliptin + metformin 
(N = 885, 54 weeks)[16] 
Sitagliptin 100 mg + metformin 2000 mg 1.9 
Sitagliptin 100 mg 1.4 
Metformin 2000 mg 1.6 
Sitagliptin + metformin 
(N = 1091, 24 weeks)[11] 
Sitagliptin 100 mg + metformin 2000 mg 2.1b 
Sitagliptin 100 mg 0.8 
Metformin 2000 mg 1.3 
Sitagliptin + metformin 
(N = 1250, 18 weeks)[13] 
Sitagliptin 100 mg + metformin 2000 mg 2.4b 
Metformin 2000 mg 1.8 
Vildagliptin + pioglitazone 
(N = 607, 24 weeks)[14] 
Vildagliptin 100 mg + pioglitazone 30 mg 1.7c 
Vildagliptin 100 mg 1.1 
Pioglitazone 30 mg 1.4 
Alogliptin + pioglitazone 
(N = 655, 26 weeks)[10] 
Alogliptin 25 mg + pioglitazone 30 mg 1.7b 
Alogliptin 25 mg 1.0 
Pioglitazone 30 mg 1.2 
a Therapeutic doses represent maximum daily dose. 
b P < .05 vs monotherapy. 
c P < .05 vs pioglitazone. 
d Doses may be titrated as follows: metformin [500-2000 mg] and rosiglitazone [2-8 mg].
HbA1C = Hemoglobin A1c [glycated hemoglobin]. 
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Appendix L 
Participant Instructions and Flow of Simulators  
The following screen shots represent the instructions given to participants of the study: 
 
 
153 
 
 
  
 
 
 
 
154 
 
 
  
 
 
155 
 
 
  
Appendix M 
System Database Design and Layout 
 
MySQL Table: C2C_Random 
 
Server: sql5c40a.carrierzone.com Database: C2C_Random_jtemplet_site_aplus_net 
Table: C2C_Random  
C2C_Random 
Field Type Null Default 
Primary  int(11) No    
Random  varchar(10) No    
current  int(11) No    
 
 
Indexes:  
Keyname Type Cardinality Field 
PRIMARY PRIMARY 3 Primary 
 
Space usage:  
Type Usage 
Data 60 B 
Index 2,048 B 
Total 2,108 B 
 
  
Row Statistics:  
Statements Value 
Format dynamic  
Rows 3 
Row length ø 20  
Row size  ø 703 B 
Creation Feb 18, 2010 at 04:26 PM 
Last update Mar 23, 2010 at 04:38 PM 
 
 
 
MySQL Table: C2P_Random 
 
Server: sql5c40a.carrierzone.com Database: C2P_Random_jtemplet_site_aplus_net 
Table: C2P_Random  
C2P_Random 
Field Type Null Default 
Primary  int(11) No    
Random  varchar(10) No    
current  int(11) No    
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Indexes:  
Keyname Type Cardinality Field 
PRIMARY PRIMARY 3 Primary 
 
Space usage:  
Type Usage 
Data 60 B 
Index 2,048 B 
Total 2,108 B 
 
  
Row Statistics:  
Statements Value 
Format dynamic  
Rows 3 
Row length ø 20  
Row size  ø 703 B 
Creation Dec 5, 2009 at 04:08 PM 
Last update Mar 23, 2010 at 09:09 AM 
 
 
MySQL Table: Clinician_Strat 
 
Server: sql5c40a.carrierzone.com Database: 
Clinician_Strat_jtemplet_site_aplus_net Table: Clinician_Strat  
Clinician_Strat 
Field Type Null Default 
Primary  tinyint(1) No    
Strat  varchar(10) No    
Current  int(11) No    
 
 
Indexes:  
Keyname Type Cardinality Field 
PRIMARY PRIMARY 2 Primary 
 
Space usage:  
Type Usage 
Data 40 B 
Index 2,048 B 
Total 2,088 B 
 
  
Row Statistics:  
Statements Value 
Format dynamic  
Rows 2 
Row length ø 20  
Row size  ø 1,044 B 
Creation Dec 5, 2009 at 02:49 PM 
Last update Mar 23, 2010 at 08:41 PM 
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MySQL Table: P2C_Random 
 
Server: sql5c40a.carrierzone.com Database: P2C_Random_jtemplet_site_aplus_net 
Table: P2C_Random  
P2C_Random 
Field Type Null Default 
Primary  int(11) No    
Random  Varchar(10) No    
current  int(11) No    
 
 
Indexes:  
Keyname Type Cardinality Field 
PRIMARY PRIMARY 3 Primary 
 
Space usage:  
Type Usage 
Data 60 B 
Index 2,048 B 
Total 2,108 B 
 
  
Row Statistics:  
Statements Value 
Format dynamic  
Rows 3 
Row length ø 20  
Row size  ø 703 B 
Creation Dec 5, 2009  at 03:30 PM 
Last update Mar 23, 2010 at 10:55 PM 
 
 
 
MySQL Table: cardlist5 
 
Server: sql5c40a.carrierzone.com Database: gcard_jtemplet_site_aplus_net 
Table: cardlist5  
cardlist5 
Field Type Null Default 
id  int(3) No    
code  varchar(20) No    
status  varchar(10) No    
Value  int(3) No    
 
 
Indexes:  
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Keyname Type Cardinality Field
PRIMARY PRIMARY 54 id  
code  UNIQUE 54 code 
 
Space usage:  
Type Usage 
Data 2,008 B 
Index 6,144 B 
Total 8,152 B 
 
  
Row Statistics:  
Statements Value 
Format dynamic  
Rows 54 
Row length ø 37  
Row size  ø 151 B 
Next Autoindex 55 
Creation Dec 05, 2009 at 11:44 PM 
Last update Mar 23, 2010 at 04:54 PM 
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Appendix N 
Simulated Telemedicine Layout/Page Properties (Note: Numerous formatting 
features of HTML page adjusted to fit into document) 
Patient Information: 
Patient J.R. is a 35 year old 
Hispanic male who is newly 
diagnosed with Type 2 DM. 
He is naïve to drug 
treatment and currently has 
an A1c = 9.0%. Patient 
would like to seek treatment 
options other than insulin.  
Clinical 
Presentation: 
Patient is a 35 y.o. 
obese Hispanic male 
who presents for 
routine diabetes care 
follow up. Patient 
diagnosed with Type 2 
Diabetes Mellitus four 
months prior to visit. 
Social History: 
Patient is married with two 
children, ages 7 and 9. Patient is 
acutely aware of diabetes 
complications, as father had foot 
amputation at age 45 while patient 
was a teenager. He is self-
employed as an electrician and is 
concerned about potential loss of 
income due to manifestations of 
disease complications. He feels 
encouraged to manage his Type 2 
DM with lifestyle changes and 
oral medication. 
Patient History: 
Patient diagnosed with Type 
2 Diabetes Mellitus four 
months ago and is returning 
for follow up visit. Diet and 
exercise have resulted in 
modest improvements in 
weight loss of 8 lbs. Patient 
is also being treated for 
dyslipidemia and 
hypertension. Family history 
of diabetes. 
Current 
Medications: 
 Atorvastatin: 10 
mg once daily 
(cholesterol) 
 Amlodipine: 5 
mg once daily 
(blood pressure) 
Physical Exam and Review 
of Systems: 
 Overweight Hispanic Male 
in no acute distress 
 Height = 66" 
 Weight = 249 lbs 
 BMI = 40.2 kg/m2 
 BP = 142/80 (controlled 
with CCB) 
 HR = 77 beats per minute 
and regular 
 Respiratory rate = 14 
breaths per minute and 
regular 
 HEENT Exam = Normal 
 Lung and Abdominal 
exams unremarkable 
 Foot exam normal 
 Patient denies nausea, 
vomiting, fatigue, 
melancholy, and syncope 
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 Most recent eye exam (1 
year ago) revealed no 
indication of diabetic 
retinopathy  
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Lab Values:  
 HbA1c = 9.0% 
 FPG = 140 mg/dl 
 PPG = 240-272 mg/dl 
 T-C = 248 mg/dl 
 LDL-C = 110 mg/dl 
 HDL-C = 34 mg/dl 
 TG = 194 mg/dl 
 Electrolytes, WBC, urinary 
albumin, serum creatinine, and 
BUN are within normal ranges 
Three month goal attainment - 
management: 
Despite initial hopes to manage blood glucose, 
the patient has been unable to adequately 
manage weight loss and glucose levels. In 
consulting with the patient, a course of therapy 
which includes oral agents has been agreed 
upon along with a more aggressive diet and 
exercise routine. Patient will be meeting with 
dietician next week to discuss meal plan and 
further education. 
Goals of treatment:  
 minimize risk and severity of hypoglycemia 
 minimize risk and magnitude of weight gain 
 inclusion of major classes of FDA approved glycemic medications, including 
incretin-based therapies and thiazolidinediones TZDs 
 selection of therapy stratified by hemoglobin A1c and based on documented A1c-
lowering potential 
 consideration of both fasting and postprandial glucose levels as end points 
 consideration of total cost of therapy to the individual and society at large, 
including costs related to medications, glucose monitoring requirements, 
hypoglycemic events, drug-related adverse events, and treatment of diabetes-
associated complications 
 clinical judgment and experience 
Recommendations:  
It is recommended that the patient be placed on combination oral therapy. This course 
may be the most appropriate given the level of glucose control that is necessary. The 
current A1c is at 9%, pointing to a high probability of adverse outcomes. The optimal 
level and goal for A1c should be 6.5%, a reduction of 2.5% from current levels.  
Monotherapy alone may not help the patient reach this goal. Given the patient preference 
to avoid insulin, this may be the most appropriate direction.  
The recommended combination therapy is:  
- Saxagliptin 10 mg + Metformin 2000 mg, once daily, titrated from lower 
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dose (initial dose: saxagliptin 2.5 mg + metformin 500 mg titrated weekly) 
- Increase dose of atorvastatin to provide tighter control of lipids  
- Increase dose of amlodipine to provide tighter control of hypertension  
Based on randomized clinical trials (RCT), our goal should be to reduce A1c by 2.5% to 
reach a target of 6.5% or less. 
Review of Symptoms (ROS) - Clinician should explore further the following potential 
symptoms to uncover overt or occult signs of complications: 
o Chest pain (CP) 
o Dyspnea on Exertion (DOE) 
o Shortness of Breath (SOB) 
o Urinary and Ophthalmologic issues 
o Dietary Review - make sure patient does not attempt radical weight loss 
diet 
o Adverse Event from Medication/Diet - Concomitant medical therapies or 
diet such as the (i.e. Grapefruit Diet), which could cause issues with 
metabolism such as CYP3A4 pathway (i.e. complications from statin 
therapy such as myalgia). 
o Liver Function Test (LFT) - to monitor statin 
o Family History of Stroke/Ischemia/Infarct - detailed explanation of risk 
o Consider Cardiovascular Stress Test to determine baseline risk 
stratification 
o Concomitant medications- especially herbal/over-the-counter medications 
It is further recommended that the treating clinician discuss with the patient the potential 
benefits of tighter control with insulin. Discussion and education from this perspective 
may help to prepare the patient for the addition of insulin, which is a real possibility in 
this case.
Markov Chain Monte Carlo Risk Calculation  
Low Risk Low Risk Borderline Risk Moderate Risk
Moderately 
High Risk High R
Patient is at HIGH RISK: Primary risk factors include blood sugar (HbA1c) value 
(9.0%), (SBP) systolic blood pressure (142 mmHg), (T-C) total cholesterol (248 mg/dl), 
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and HDL-C (34 mg/dl). Primary focus should be the lowering of HbA1c to <6.5% and to 
consider tighter control for blood pressure and lipid management. 
Markov Chain Monte Carlo (MCMC) Risk Calculations attempt to predict the probability 
of a future events based on current states. Results shown are the estimated risk of having 
a heart attack, stroke, or negative outcome within 10 years. This result is NOT a 
prediction but rather a calculated estimate of the future risk. It is based upon the large 
scale studies called United Kingdom Prospective Diabetes Study (UKPDS) as well as the 
Framingham Heart Study. The primary weighting is placed on blood sugar (HbA1c), 
blood pressure, total cholesterol, and HDL-C. Risk calculation predictive values increase 
in accuracy with a greater number of measured and validated data points included in the 
calculation. These results may be skewed by the limited quantity or quality of 
information available. 
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Reasoning/Justification of treatment: 
The following table represents an examination of RCTs with combination therapy in 
naïve patients:  
Randomized Controlled Trial -  
ug Combination Therapy in Naïve Patients
Total HbA1c Decreases (%)a 
Rosiglitazone + metformin 
(N = 468, 32 weeks)[15] 
Rosiglitazone 8 mg + metformin 2000 mgd 
Rosiglitazone 8 mgd 
Metformin 2000 mgd 
Rosiglitazone + glimepiride 
(N = 901, 28 weeks) [9] 
Rosiglitazone 8 mg + glimepiride 4 mg 
Rosiglitazone 8 mg 
Glimepiride 4 mg 
Saxagliptin + metformin 
(N = 1306, 24 weeks)[12] 
Saxagliptin 10 mg + metformin 
Saxagliptin 10 mg 
Metformin 2000 mg 
Vildagliptin + metformin  
(N = 1179, 24 weeks)[8] 
Vildagliptin 100 mg + metformin 2000 mg 
Vildagliptin 100 mg 
Metformin 2000 mg 
Sitagliptin + metformin 
(N = 885, 54 weeks)[16] 
Sitagliptin 100 mg + metformin 2000 mg 
Sitagliptin 100 mg 
Metformin 2000 mg 
Sitagliptin + metformin 
(N = 1091, 24 weeks)[11] 
Sitagliptin 100 mg + metformin 2000 mg 
Sitagliptin 100 mg 
Metformin 2000 mg 
Sitagliptin + metformin 
(N = 1250, 18 weeks)[13] 
Sitagliptin 100 mg + metformin 2000 mg 
Metformin 2000 mg 
Vildagliptin + pioglitazone 
(N = 607, 24 weeks)[14] 
Vildagliptin 100 mg + pioglitazone 30 mg 
Vildagliptin 100 mg 
Pioglitazone 30 mg 
Alogliptin + pioglitazone 
(N = 655, 26 weeks)[10] 
Alogliptin 25 mg + pioglitazone 30 mg 
Alogliptin 25 mg 
Pioglitazone 30 mg 
erapeutic doses represent maximum daily dose. 
< .05 vs monotherapy. 
< .05 vs pioglitazone. 
oses may be titrated as follows: metformin [500mg - 2000 mg] and rosiglitazone [2 mg - 8 m
= Hemoglobin A1c [glycated hemoglobin]. 
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Patient Progress and Update: 
You were diagnosed with diabetes 4 months ago. As 
your clinician, I will work closely with you to help 
manage this disease. With the right combination of 
education, diet, exercise, medication, awareness, and 
action, you can live a full and productive life, free 
from many of the complications that diabetes can 
produce. 
Patient Awareness and Action: 
The initial point of being diagnosed with diabetes can 
be overwhelming and stressful. But don't give up. 
Diabetes is a disease that can be managed and dealt 
with, but it is important that you play an active role in 
managing your diabetes. Education is key and so is 
following the directions of your clinical team. We are 
always here to help you understand and manage your 
diabetes, but without you we can't help.  
Patient Education: 
As a patient with diabetes, it is important that you understand what the disease is and what it does to you. First 
off, know that you are not alone. According to the American Diabetes Association, millions of Americans 
have been diagnosed with diabetes and even more don't even know that they are at high risk for diabetes.  
Certain groups of people have a higher risk for developing Type 2 diabetes: African Americans, Latinos, 
Native Americans, Asian Americans, Native Hawaiians and other Pacific Islanders, as well as the elderly. 
What is diabetes and why did I get it? This is a common question. There are several different forms of 
diabetes, however the most common form, and the form that you were diagnosed with, is called Type 2 
diabetes. Type 2 diabetics have one of two problems, both having to do with a hormone called insulin. Either 
your body does not produce enough insulin or the cells in your body reject the insulin. Some people even have 
both problems.  
What is insulin? Insulin is a hormone that is found in your body. Whenever you eat food, your body breaks 
down the starches and sugars into glucose. Glucose is also called blood sugar and it is the fuel that your body 
needs to supply energy to all of the different parts, like your cells. However, the doors to your cells are locked 
and glucose can't get in by itself. That is where insulin comes in; it acts as the key to open the cell and allows 
the glucose to come in and provide energy to the cell. Without insulin, the glucose would not be able to enter 
the cell; it would simply build up in the blood causing your blood sugar, or glucose, to rise. This is where the 
dangers of diabetes complications come in. Your cells are not getting the nutrients and fuel that are necessary, 
and over time the cells become damaged by this lack of energy.  
Various parts of your body are at more risk from the damage over time from diabetes. This includes your eyes, 
heart, kidneys, feet, skin, blood pressure, and even your mental health. These areas suffer because, over time, 
diabetes starves these regions of much needed fuel and energy, causing them to break down and creating 
serious problems for the diabetic patient. Heart disease and stroke are the leading causes of death to diabetics. 
These complications can be managed and delayed if you take the time to learn how to alter your lifestyle to 
and improve your health.  
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Lab Values and what they mean: 
 HbA1c = 9.0%  
o Glycosated hemoglobin or A1C (A1C is the standard name). This test gives a long term (say 3 
month) idea of how well you are controlling your blood sugar. As a diabetic, your goal is 6.5%, 
or as close to it as possible. Your value is too high so we need to reduce it. This will be done by 
a combination of therapies, including diet, exercise, oral medication, or insulin. 
 FPG = 140 mg/dl  
o Fasting Plasma Glucose is a test to measure how much glucose (sugar) is present in the blood. 
The test is normally given in the morning when you have not eaten in 8 hours. Normal ranges 
for blood sugar would be less than 100 mg/dl, levels above 126 mg/dl usually indicate diabetes. 
Yours is at 140 mg/dl, which is a key indicator that you suffer from diabetes. This test was 
taken at your last doctor's visit. You may have heard this test referred to as a Fasting Blood 
Sugar. 
 PPG = 240-272 mg/dl  
o Postprandial Plasma Glucose is another test that measures the amount of glucose (sugar) in your 
blood, but this time it is taken within two hours of eating a meal. Normal values are less than 
140 mg/dl. Your values are between 240-272 mg/dl and are considered HIGH.  
 T-C = 248 mg/dl  
o Total Cholesterol is the total amount of cholesterol in the blood. Cholesterol is called a lipid, or 
fat, and is important to watch because too much cholesterol in your blood means that your 
arteries may become blocked. Your level of 248 mg/dl is considered HIGH RISK. When you 
add diabetes to the list, it becomes even more important to manage your cholesterol levels. Our 
goal is that diet and exercise will lower this value below 200 mg/dl. If not, we may need to add 
to your medications to help. 
 LDL-C = 110 mg/dl  
o Low Density Lipoprotein - Cholesterol is part of the total cholesterol value above and is often 
referred to as "BAD" cholesterol. Anything less than 100 mg/dl is considered optimal; your 
value of 110 mg/dl is NEAR-OPTIMAL. This value is actually quite good. 
 HDL-C = 34 mg/dl  
o High Density Lipoprotein - Cholesterol is also part of the total cholesterol value above and is 
often referred to as the "GOOD" cholesterol. HDL seems to have a protective property that 
helps to keep things in check. Unlike the other values associated with cholesterol, we want this 
value to be higher. Any value over 40 mg/dl is considered good in men, while a value over 50 
mg/dl in women is better. A value of 60 mg/dl has shown to give protection against heart 
disease. We need to work on improving this value. Your dietician will help you to develop a 
healthy diet which may help in this area.  
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 TG = 194 mg/dl  
o Triglycerides are another area of the total cholesterol value above. Triglycerides are another 
form of fat and often go along with a higher total cholesterol value when they are elevated. 
Your value of 194 mg/dl is considered HIGH. The normal range is less than 150 mg/dl. 
Triglycerides are easily influenced by lifestyle changes. I encourage you to watch your diet and 
eat healthy foods in order to improve these numbers. If diet and exercise alone cannot reduce 
your cholesterol levels, including your triglyceride levels, we may have to add some medication 
to help. 
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Three month goal attainment - management: 
Despite initial hopes to manage blood glucose levels by diet and exercise, your glucose levels are still 
dangerously high. We need to start a course of therapy which includes oral agents, so that we can control your 
HbA1c levels, as well as a more aggressive diet and exercise routine. Meeting with your dietician next week to 
discuss meal plans and further education should also help get you started. 
Goals of treatment:  
 Minimize risk and severity of hypoglycemia: We don't want your blood sugar (glucose) to drop too 
low, as this can cause major health problems.  
 Minimize risk and magnitude of weight gain: Managing your weight is tough, and certain diabetes 
medications make it even more difficult to manage your weight. So we need to keep on eye on which 
treatment options we utilize. 
 Inclusion of major classes of FDA approved glycemic medication: We only want to use safe, proven 
therapies that work and are approved by the FDA to be used for diabetes. 
 Selection of therapy stratified by hemoglobin A1c and based on documented A1c-lowering potential: 
We want to focus on the long term effects, not just the short term effects. 
 Consideration of both fasting and postprandial glucose levels as end points: We want to examine the 
effects of your diabetes both after you eat (postprandial) as well when you have been fasting as they are 
all important. 
 Consideration of total cost of therapy to the individual and society at large, including costs related to 
medications, glucose monitoring requirements, hypoglycemic events, drug-related adverse events, and 
treatment of diabetes-associated complications: We want to select treatments that not only work, but 
are affordable and attainable to you. Without that you are unlikely to be successful with your treatment.
 Clinical judgment and experience: We want to rely on the knowledge and expertise of your clinical 
team which includes your doctor, nurse, diabetes educator, dietician, and others who advocate for your 
health. 
Recommendations: 
First, let's schedule time for you to meet with your dietician to plan out a meal and exercise routine. You will 
need to also visit the eye doctor to get an exam. 
Education is key to dealing with diabetes. We will use this system combined with face to face meetings to help 
you better manage your diabetes.  
I also recommend that you begin taking a combination of oral medication. My recommendations for you are 
based on two main factors: your elevated A1C levels of 9.0% and your elevated PPG (blood glucose levels 
after eating). Diet and exercise are unlikely to lower your levels to an appropriate level. This course may be 
the most appropriate given the level of glucose control that is necessary. Your current A1c is at 9% and we 
need to do something to reduce it to goal. The optimal level and goal for A1c should be 6.5% which is a 
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reduction of 2.5% from your current levels.  
We will start with oral medication to see if that can work, if not we may need to include insulin into your 
therapy. We will determine that as we continue to monitor and treat your diabetes. 
The recommended combination therapy is:  
- Saxagliptin 10 mg + Metformin 2000 mg, once daily (diabetes medication) 
- Atorvastatin 10 mg, once daily (cholesterol medication)  
- Amlodipine 10 mg, once daily (blood pressure medication) 
We will start with lower doses and work our way up to avoid side effects and to also determine how well it is 
working. You may not need that much medicine, so we will take our time and slowly increase the dosage to 
the maximum above.  
We may also need to consider including insulin into your therapy. During our next discussion, we will begin to 
educate you on some of the other choices. 
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